valproic acid has been researched along with Absence Status in 266 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous phenobarbital is frequently offered to patients with generalized convulsive status epilepticus (GCSE) in China, but its long-term benefits are unclear." | 9.69 | Long-term follow-up of phenobarbital versus valproate for generalized convulsive status epilepticus in adults: A randomized clinical trial. ( Chen, W; Huang, H; Jiang, M; Liu, G; Su, Y; Tian, F; Wang, Y; Zhang, Y, 2023) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus." | 9.41 | Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ( Babcock, L; Brundage, RC; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Elm, JJ; Fountain, NB; Ivaturi, V; Kapur, J; Lowenstein, DH; Mishra, U; Sathe, AG; Shinnar, S; Silbergleit, R, 2021) |
| "To compare the efficacy of phenytoin, valproate, and levetiracetam in the management of pediatric convulsive status epilepticus." | 9.34 | Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial. ( Mahadevan, S; Rameshkumar, R; Vignesh, V, 2020) |
| "Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients." | 9.34 | Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. ( Babcock, L; Barsan, W; Bleck, TP; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, NB; Holsti, M; Kapur, J; Lowenstein, D; Meinzer, C; Rogers, A; Shinnar, S; Silbergleit, R; Underwood, E, 2020) |
| "The Established Status Epilepticus Treatment Trial was a blinded, comparative-effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodiazepine-refractory status epilepticus." | 9.34 | The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. ( Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Sathe, AG; Shinnar, S; Silbergleit, R, 2020) |
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 9.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| ") sodium valproate (VPA) for diazepam (DZP) refractory convulsive status epilepticus (CSE)." | 9.14 | Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. ( Chen, L; Feng, P; Liu, L; Wang, J; Zhou, D, 2009) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 9.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "Sixty-eight patients with convulsive status epilepticus (SE) were randomly assigned to two groups to study the efficacy of sodium valproate (VPA) and phenytoin (PHT)." | 9.12 | Sodium valproate vs phenytoin in status epilepticus: a pilot study. ( Kalita, J; Misra, UK; Patel, R, 2006) |
| "An open-label, randomized controlled study was conducted at a tertiary care teaching hospital to compare efficacy and safety of intravenous sodium valproate versus diazepam infusion for control of refractory status epilepticus." | 9.12 | Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. ( Mehta, V; Singhi, P; Singhi, S, 2007) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 8.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose." | 8.82 | Efficacy of rapid IV administration of valproic acid for status epilepticus. ( Burneo, JG; Faught, E; Gomez, CR; Limdi, NA; Shimpi, AV, 2005) |
| "Valproic acid (VA) has been reported to be effective in status epilepticus (SE) when given rectally." | 8.80 | The role of intravenous valproic acid in status epilepticus. ( Yamamoto, LG; Yim, GK, 2000) |
| "Valproic acid (VPA) represents one of the most efficient antiseizure medications (ASMs) for both general and focal seizures, but some patients may have inadequate control by VPA monotherapy." | 8.12 | Neural excitatory rebound induced by valproic acid may predict its inadequate control of seizures. ( Chen, L; Cui, Z; Guo, Y; Jiang, S; Ke, Z; Liu, Y; Mao, Y; Tong, Y; Wang, D; Wu, Z; Zhang, H; Zhu, Z; Zou, X, 2022) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 8.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "In this report, we describe the diagnosis, investigation and management of a patient presenting with refractory status epilepticus secondary to a previously unrecognised urea cycle defect, ornithine transcarbamylase deficiency, causing a hyperammonaemic encephalopathy." | 8.02 | Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect. ( Beddoes, P; Nerone, G; Tai, C, 2021) |
| "The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy." | 7.91 | Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. ( Caminha Nunes, E; Cilio, MR; Oldham, MS; Rahdari, S; Sands, TT; Tilton, N, 2019) |
| "The aim of the study was to examine the frequency of hyperammonemia secondary to valproic acid treatment in status epilepticus and to describe the characteristics of the patients." | 7.91 | Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. ( Lind, J; Nordlund, P, 2019) |
| " In this study, we examined the effects of LEV on neuroinflammation and phagocytic microglia in vivo and in vitro and compared the effects of LEV with those of representative antiepileptic drugs valproate (VPA) and carbamazepine (CBZ)." | 7.91 | Suppressive effects of levetiracetam on neuroinflammation and phagocytic microglia: A comparative study of levetiracetam, valproate and carbamazepine. ( Ishihara, Y; Itoh, K; Matsuo, T; Oguro, A; Taniguchi, R; Vogel, CFA; Yamazaki, T, 2019) |
| "Because of the lack of studies comparing the efficacy and safety of levetiracetam and valproate before the induction of general anesthesia in the treatment of convulsive refractory status epilepticus in children, we aimed to compare the effectiveness of these antiepileptic drugs in patients with convulsive status epilepticus admitted to the Pediatric Intensive Care Unit between 2011 and 2014." | 7.83 | A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children. ( Ağın, H; Ceylan, G; Güzel, O; İşgüder, R; Yılmaz, Ü, 2016) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 7.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "Levetiracetam has been reported to be well tolerated and effective in status epilepticus (SE) refractory to benzodiazepine." | 7.79 | The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus. ( Choi, HC; Kang, TC; Kim, JE; Kim, YI; Lee, DS; Ryu, HJ; Song, HK, 2013) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 7.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| "Following cefepime therapy, a clinically important interaction between meropenem and valproic acid occurred in two critically ill patients with new-onset status epilepticus." | 7.74 | Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus. ( Casteels, M; De Troy, E; Meersseman, W; Spriet, I; Willems, L; Wilmer, A, 2007) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 7.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| "The authors herein present two children with mild absence epilepsy, having intermittent absences, who developed absence status evolving into atonic generalized seizures and drop attacks along with progressive disorientation induced by relatively small doses of valproic acid." | 7.71 | Valproic acid therapy inducing absence status evolving into generalized seizures. ( Andraus, J; Sagie-Lerman, T; Savitzki, D; Shahar, E, 2002) |
| "Three weeks after diagnosis of nonconvulsive status epilepticus, general anesthesia was induced with propofol and titrated to burst suppression on the electroencephalogram (EEG)." | 7.70 | Treatment of refractory complex-partial status epilepticus with propofol: case report. ( Begemann, M; Rowan, AJ; Tuhrim, S, 2000) |
| "An epileptic patient well controlled on valproic acid (VPA) developed a prolonged episode of status epilepticus 12 days after initiation of 75 mg of clomipramine (CMI) to treat depression." | 7.69 | Status epilepticus associated with the combination of valproic acid and clomipramine. ( DeToledo, JC; Haddad, H; Ramsay, RE, 1997) |
| "We report on a 33-year-old female suffering from frequent complex-partial seizures who developed a non-convulsive status epilepticus after one week of antiepileptic therapy with valproate (VPA) which had been added to a basic medication with barbexaclone (BBC) in rapidly increasing dosage." | 7.68 | Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus. ( Steinhoff, BJ; Stodieck, SR, 1993) |
| "The efficacy of valproic acid (VPA) in control of generalized convulsive status epilepticus was tested in a rat model." | 7.68 | Valproic acid treatment of experimental status epilepticus. ( Treiman, DM; Walton, NY, 1992) |
| "Ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that has been safely used for the treatment of refractory SE in adults and children." | 7.01 | Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. ( Brisca, G; Buratti, S; Giacheri, E; Mancardi, MM; Moscatelli, A; Nobili, L; Palmieri, A; Riva, A; Striano, P; Tibaldi, J, 2023) |
| "Primary outcome was seizure cessation for 1h, and secondary outcomes were 24h seizure remission, in-hospital death, and severe adverse events (SAE)." | 6.84 | Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study. ( Dubey, D; Kalita, J; Misra, UK, 2017) |
| "Although generalized convulsive status epilepticus (GCSE) is a life-threatening emergency, evidence-based data to guide initial drug treatment choices are lacking in the Chinese population." | 6.82 | Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China. ( Chen, W; Chun, B; Gao, D; Jiang, M; Liu, G; Ren, G; Su, Y; Tian, F; Ye, H; Zhang, Y, 2016) |
| " However, these medications have several well-known adverse effects." | 6.77 | Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. ( Ashrafi, MR; Bavarian, B; Ghaempanah, M; Khosroshahi, N; Malamiri, RA; Nikkhah, A, 2012) |
| "No patient in the VPA group developed respiratory depression, hypotension, or hepatic dysfunction, whereas in the DZP group, 5." | 6.76 | Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. ( Chen, WB; Fan, CQ; Gao, R; Ren, Y; Su, YY; Wang, L; Zhang, YZ; Zhao, JW, 2011) |
| "Valnoctamide has a stereoselective PK with (2S,3S)-VCD exhibiting the lowest clearance and, consequently, a twice-higher plasma exposure than all other stereoisomers." | 6.52 | The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. ( Bialer, M; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Yagen, B, 2015) |
| "Intravenous phenobarbital is frequently offered to patients with generalized convulsive status epilepticus (GCSE) in China, but its long-term benefits are unclear." | 5.69 | Long-term follow-up of phenobarbital versus valproate for generalized convulsive status epilepticus in adults: A randomized clinical trial. ( Chen, W; Huang, H; Jiang, M; Liu, G; Su, Y; Tian, F; Wang, Y; Zhang, Y, 2023) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 5.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| " Consequently, in the current study a comparative pharmacokinetic (PK)-pharmacodynamic analysis of SPD was conducted following i." | 5.43 | Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ( Bialer, M; Bibi, D; Blotnik, S; Mawasi, H; Shaul, C; Shekh-Ahmad, T, 2016) |
| "Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus." | 5.41 | Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ( Babcock, L; Brundage, RC; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Elm, JJ; Fountain, NB; Ivaturi, V; Kapur, J; Lowenstein, DH; Mishra, U; Sathe, AG; Shinnar, S; Silbergleit, R, 2021) |
| " This study describes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmacokinetic (PK) analysis of four individual SPD stereoisomers." | 5.39 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. ( Bialer, M; Finnell, RH; Hen, N; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, B; Yagen, B, 2013) |
| "Better treatment of status epilepticus (SE), which typically becomes refractory after about 30 min, will require new pharmacotherapies." | 5.39 | A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. ( Bialer, M; Dudek, FE; Hen, N; Kaufmann, D; Nelson, C; Pouliot, W; Ricks, K; Roach, B; Shekh-Ahmad, T; Yagen, B, 2013) |
| "To compare the efficacy of phenytoin, valproate, and levetiracetam in the management of pediatric convulsive status epilepticus." | 5.34 | Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial. ( Mahadevan, S; Rameshkumar, R; Vignesh, V, 2020) |
| "Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients." | 5.34 | Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. ( Babcock, L; Barsan, W; Bleck, TP; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, NB; Holsti, M; Kapur, J; Lowenstein, D; Meinzer, C; Rogers, A; Shinnar, S; Silbergleit, R; Underwood, E, 2020) |
| "The Established Status Epilepticus Treatment Trial was a blinded, comparative-effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodiazepine-refractory status epilepticus." | 5.34 | The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. ( Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Sathe, AG; Shinnar, S; Silbergleit, R, 2020) |
| "In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines." | 5.30 | Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. ( Barsan, W; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, N; Kapur, J; Lowenstein, D; Meinzer, C; Shinnar, S; Silbergleit, R, 2019) |
| "This randomized control study was conducted to compare the efficacy of sodium valproate (SVP) and levetiracetam (LEV) following initial intravenous lorazepam in elderly patients (age: >60years) with generalized convulsive status epilepticus (GCSE) and to identify predictors of poor seizure control." | 5.30 | Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. ( Bharath, RD; Bindu, PS; Mundlamuri, RC; Nagappa, M; Nene, D; Prathyusha, PV; Raghavendra, K; Saini, J; Satishchandra, P; Sinha, S; Taly, AB; Thennarasu, K, 2019) |
| "Based on low quality evidence, phenobarbital appears to be the most effective agent for seizure cessation within 60 min of administration in patients with benzodiazepine resistant status epilepticus." | 5.22 | Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses. ( Aneja, S; Arya, R; Cunningham, J; Jain, P; Sharma, S, 2022) |
| "This article will review the different therapeutic options for status, from early treatment at home to the different first-line (benzodiazepines), second-line (phenobarbital, valproic acid, phenytoin, levetiracetam and lacosamide) or third-line treatments, which include both pharmacological (anaesthetics, propofol, ketamine, lidocaine, topiramate, brivaracetam or perampanel) and non-pharmacological (ketogenic diet, immunomodulatory treatments or epilepsy surgery) therapies." | 5.22 | [Paediatric status epilepticus]. ( García-Peñas, JJ; González-Alguacil, E; Soto-Insuga, V, 2022) |
| "We report the efficacy and safety of lorazepam (LOR), phenytoin (PHT), valproate (VPA) and levetiracetam (LEV) as first and second choice antiepileptic drug (AED) in status epilepticus (SE) and their combinations in preventing refractory SE." | 5.22 | A comparison of four antiepileptic drugs in status epilepticus: experience from India. ( Kalita, J; Misra, UK, 2016) |
| ") sodium valproate (VPA) for diazepam (DZP) refractory convulsive status epilepticus (CSE)." | 5.14 | Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. ( Chen, L; Feng, P; Liu, L; Wang, J; Zhou, D, 2009) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 5.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "Sixty-eight patients with convulsive status epilepticus (SE) were randomly assigned to two groups to study the efficacy of sodium valproate (VPA) and phenytoin (PHT)." | 5.12 | Sodium valproate vs phenytoin in status epilepticus: a pilot study. ( Kalita, J; Misra, UK; Patel, R, 2006) |
| "An open-label, randomized controlled study was conducted at a tertiary care teaching hospital to compare efficacy and safety of intravenous sodium valproate versus diazepam infusion for control of refractory status epilepticus." | 5.12 | Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. ( Mehta, V; Singhi, P; Singhi, S, 2007) |
| "The intravenous application of VPA seems to be an easy-to-use, safe and efficient formulation as an alternative to phenytoin in all seizure emergency situations including status epilepticus." | 5.11 | Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus--experience in 102 adult patients. ( Peters, CN; Pohlmann-Eden, B, 2005) |
| "Valproic acid (VPA) and warfarin are commonly prescribed for patients with epilepsy and concomitant atrial fibrillation (AF)." | 4.98 | The critical interaction between valproate sodium and warfarin: case report and review. ( Dong, C; Ren, L; Song, P; Sui, Y; Sun, X; Xu, B; Zhao, W; Zhou, C, 2018) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 4.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Starting with the established antiepileptic drug, valproic acid, we have taken a novel approach to develop new antiseizure drugs that may be effective in status epilepticus." | 4.91 | New experimental therapies for status epilepticus in preclinical development. ( Walker, MC; Williams, RS, 2015) |
| "Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose." | 4.82 | Efficacy of rapid IV administration of valproic acid for status epilepticus. ( Burneo, JG; Faught, E; Gomez, CR; Limdi, NA; Shimpi, AV, 2005) |
| " Search terms included valproate, valproic acid, and status epilepticus." | 4.81 | Intravenous valproate in status epilepticus. ( Hodges, BM; Mazur, JE, 2001) |
| "Valproic acid (VA) has been reported to be effective in status epilepticus (SE) when given rectally." | 4.80 | The role of intravenous valproic acid in status epilepticus. ( Yamamoto, LG; Yim, GK, 2000) |
| "Valproic acid (VPA) represents one of the most efficient antiseizure medications (ASMs) for both general and focal seizures, but some patients may have inadequate control by VPA monotherapy." | 4.12 | Neural excitatory rebound induced by valproic acid may predict its inadequate control of seizures. ( Chen, L; Cui, Z; Guo, Y; Jiang, S; Ke, Z; Liu, Y; Mao, Y; Tong, Y; Wang, D; Wu, Z; Zhang, H; Zhu, Z; Zou, X, 2022) |
| " Therefore, the present study hypothesized an antiepileptic potential of chondroitin sulfate (CS) in pentylenetetrazole-induced kindled epilepsy and pilocarpine-induced status epilepticus in mice." | 4.02 | Anticonvulsive Effects of Chondroitin Sulfate on Pilocarpine and Pentylenetetrazole Induced Epileptogenesis in Mice. ( Abdel-Daim, MM; Almeer, R; Kamel, M; Najda, A; Nurzyńska-Wierdak, R; Singh, M; Singh, S; Singh, TG, 2021) |
| "To test the accuracy of an equation in adult patients with status epilepticus that calculates the free concentration of serum valproic acid (fVPA) from the total concentration of serum valproic acid (tVPA) and serum albumin." | 4.02 | Accuracy of Calculated Free Valproate Levels in Adult Patients With Status Epilepticus. ( Baumann, SM; Fisch, U; Marsch, S; Rüegg, S; Semmlack, S; Sutter, R, 2021) |
| "The development of refractory status epilepticus (SE) induced by sarin intoxication presents a therapeutic challenge." | 4.02 | Neuroprotection by delayed triple therapy following sarin nerve agent insult in the rat. ( Baranes, S; Chapman, S; David, T; Dekel Jaoui, H; Efrati, R; Egoz, I; Gez, R; Gore, A; Grauer, E; Lazar, S; Neufeld-Cohen, A; Yampolsky, M, 2021) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 4.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "In this report, we describe the diagnosis, investigation and management of a patient presenting with refractory status epilepticus secondary to a previously unrecognised urea cycle defect, ornithine transcarbamylase deficiency, causing a hyperammonaemic encephalopathy." | 4.02 | Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect. ( Beddoes, P; Nerone, G; Tai, C, 2021) |
| "The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy." | 3.91 | Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US. ( Caminha Nunes, E; Cilio, MR; Oldham, MS; Rahdari, S; Sands, TT; Tilton, N, 2019) |
| "The aim of the study was to examine the frequency of hyperammonemia secondary to valproic acid treatment in status epilepticus and to describe the characteristics of the patients." | 3.91 | Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. ( Lind, J; Nordlund, P, 2019) |
| " In this study, we examined the effects of LEV on neuroinflammation and phagocytic microglia in vivo and in vitro and compared the effects of LEV with those of representative antiepileptic drugs valproate (VPA) and carbamazepine (CBZ)." | 3.91 | Suppressive effects of levetiracetam on neuroinflammation and phagocytic microglia: A comparative study of levetiracetam, valproate and carbamazepine. ( Ishihara, Y; Itoh, K; Matsuo, T; Oguro, A; Taniguchi, R; Vogel, CFA; Yamazaki, T, 2019) |
| " Pregabalin, valproic acid and levetiracetam all terminate seizures in the rat SE model and attenuate cholinergic and metabolic changes within two hours." | 3.91 | Effects of Three Anti-Seizure Drugs on Cholinergic and Metabolic Activity in Experimental Status Epilepticus. ( Imran, I; Klein, J; Koch, K; Lau, H; Schöfer, H, 2019) |
| "Because of the lack of studies comparing the efficacy and safety of levetiracetam and valproate before the induction of general anesthesia in the treatment of convulsive refractory status epilepticus in children, we aimed to compare the effectiveness of these antiepileptic drugs in patients with convulsive status epilepticus admitted to the Pediatric Intensive Care Unit between 2011 and 2014." | 3.83 | A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children. ( Ağın, H; Ceylan, G; Güzel, O; İşgüder, R; Yılmaz, Ü, 2016) |
| "Based on data from the EURAP observational International registry of antiepileptic drugs (AEDs) and pregnancy, we assessed changes in seizure control and subsequent AED changes in women who underwent attempts to withdraw valproic acid (VPA) during the first trimester of pregnancy." | 3.83 | Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2016) |
| "Pentylenetetrazol (PTZ)-induced chronic kindling model and lithium-pilocarpine-induced status epilepticus (SE) model were used in this study." | 3.81 | Degeneration and regeneration of GABAergic interneurons in the dentate gyrus of adult mice in experimental models of epilepsy. ( Jiang, W; Wang, Y; Wei, D; Wu, C; Wu, SX; Yang, F, 2015) |
| " Epileptic rats that developed spontaneous recurrent seizures after a pilocarpine-induced status epilepticus were treated with a KD or control diet (CD)." | 3.81 | Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. ( Akula, KK; Boison, D; Coffman, SQ; Lusardi, TA; Masino, SA; Ruskin, DN, 2015) |
| " She was diagnosed as having influenza encephalopathy presenting non-convulsive status epilepticus (NCSE), and commenced methylprednisolone pulse therapy followed by prednisolone with gradual tapering." | 3.80 | [Case of non-convulsive status epilepticus after influenza virus B infection]. ( Kira, J; Oyagi, Y; Shigetou, H; Tateishi, T; Uehara, T; Une, H, 2014) |
| "Levetiracetam has been reported to be well tolerated and effective in status epilepticus (SE) refractory to benzodiazepine." | 3.79 | The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus. ( Choi, HC; Kang, TC; Kim, JE; Kim, YI; Lee, DS; Ryu, HJ; Song, HK, 2013) |
| "A novel class of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in the rat maximal electroshock (MES) and subcutaneous metrazol (scMet) seizure tests and pilocarpine-induced status epilepticus (SE) model." | 3.78 | Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. ( Bialer, M; Hen, N; Yagen, B, 2012) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 3.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| " We previously showed that tolerance to levetiracetam (LEV) developed within 4 days after the start of the treatment in a rat model for spontaneous seizures after electrically induced status epilepticus." | 3.76 | Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. ( Edelbroek, PM; Gorter, JA; van Vliet, EA, 2010) |
| "Following cefepime therapy, a clinically important interaction between meropenem and valproic acid occurred in two critically ill patients with new-onset status epilepticus." | 3.74 | Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus. ( Casteels, M; De Troy, E; Meersseman, W; Spriet, I; Willems, L; Wilmer, A, 2007) |
| " In the present study, we compared the effects of riluzole and valproate (VPA) in the pilocarpine-induced limbic seizure model and in the gamma-hydroxybutyrate lactone (GBL)-induced absence seizure model." | 3.74 | Anti-glutamatergic effect of riluzole: comparison with valproic acid. ( Choi, HC; Choi, SY; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Kwak, SE; Kwon, OS; Song, HK, 2007) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "Reversible neurotoxic symptoms were observed in three adult patients with absence status epilepticus on lamotrigine (LTG) therapy after administration of an IV bolus followed by oral valproic acid (VPA)." | 3.72 | Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. ( Burneo, JG; Faught, E; Knowlton, RC; Kuzniecky, RI; Lawn, N; Limdi, N; Mendez, M; Prasad, A; Welty, TE, 2003) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 3.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| "The authors herein present two children with mild absence epilepsy, having intermittent absences, who developed absence status evolving into atonic generalized seizures and drop attacks along with progressive disorientation induced by relatively small doses of valproic acid." | 3.71 | Valproic acid therapy inducing absence status evolving into generalized seizures. ( Andraus, J; Sagie-Lerman, T; Savitzki, D; Shahar, E, 2002) |
| "We observed a young patient with slight mental retardation, suffering from drug-resistant tonic-clonic seizures, who presented a status epilepticus (SE), in two separate periods when valproic acid (VPA) was added to the phenobarbital (PB) already being used in the patient's therapy." | 3.70 | Valproate-induced epileptic tonic status. ( Balducci, A; Capocchi, G; Cecconi, M; Pelli, MA; Picchiarelli, A; Silvestrelli, G; Zampolini, M, 1998) |
| "Three weeks after diagnosis of nonconvulsive status epilepticus, general anesthesia was induced with propofol and titrated to burst suppression on the electroencephalogram (EEG)." | 3.70 | Treatment of refractory complex-partial status epilepticus with propofol: case report. ( Begemann, M; Rowan, AJ; Tuhrim, S, 2000) |
| "An epileptic patient well controlled on valproic acid (VPA) developed a prolonged episode of status epilepticus 12 days after initiation of 75 mg of clomipramine (CMI) to treat depression." | 3.69 | Status epilepticus associated with the combination of valproic acid and clomipramine. ( DeToledo, JC; Haddad, H; Ramsay, RE, 1997) |
| "We report on a 33-year-old female suffering from frequent complex-partial seizures who developed a non-convulsive status epilepticus after one week of antiepileptic therapy with valproate (VPA) which had been added to a basic medication with barbexaclone (BBC) in rapidly increasing dosage." | 3.68 | Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus. ( Steinhoff, BJ; Stodieck, SR, 1993) |
| "The efficacy of valproic acid (VPA) in control of generalized convulsive status epilepticus was tested in a rat model." | 3.68 | Valproic acid treatment of experimental status epilepticus. ( Treiman, DM; Walton, NY, 1992) |
| "Ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that has been safely used for the treatment of refractory SE in adults and children." | 3.01 | Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. ( Brisca, G; Buratti, S; Giacheri, E; Mancardi, MM; Moscatelli, A; Nobili, L; Palmieri, A; Riva, A; Striano, P; Tibaldi, J, 2023) |
| "Primary outcome was seizure cessation for 1h, and secondary outcomes were 24h seizure remission, in-hospital death, and severe adverse events (SAE)." | 2.84 | Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study. ( Dubey, D; Kalita, J; Misra, UK, 2017) |
| "Although generalized convulsive status epilepticus (GCSE) is a life-threatening emergency, evidence-based data to guide initial drug treatment choices are lacking in the Chinese population." | 2.82 | Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China. ( Chen, W; Chun, B; Gao, D; Jiang, M; Liu, G; Ren, G; Su, Y; Tian, F; Ye, H; Zhang, Y, 2016) |
| " However, these medications have several well-known adverse effects." | 2.77 | Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. ( Ashrafi, MR; Bavarian, B; Ghaempanah, M; Khosroshahi, N; Malamiri, RA; Nikkhah, A, 2012) |
| "No patient in the VPA group developed respiratory depression, hypotension, or hepatic dysfunction, whereas in the DZP group, 5." | 2.76 | Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. ( Chen, WB; Fan, CQ; Gao, R; Ren, Y; Su, YY; Wang, L; Zhang, YZ; Zhao, JW, 2011) |
| "The onset of epilepsy is most prevalent between 1 and 3 years of age; however, approximately 25% of patients developed epilepsy before one year of age." | 2.72 | Epilepsy in Angelman syndrome: A scoping review. ( Samanta, D, 2021) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| " If only valproate therapy owns the ability to obtain seizure freedom, then stopping its administration is not suggested, but a low dosage has to be aimed (500-600 mg/day, but not more than 1000 mg/day): according to some studies, most idiopathic generalized epilepsies can be controlled by low valproate dosage." | 2.55 | [Valproate in the treatment of epilepsy and status epilepticus]. ( Bóné, B; Janszky, J; Tényi, D, 2017) |
| "Convulsive status epilepticus is the most extreme form of seizure." | 2.55 | Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. ( Fung, BB; Fung, EL, 2017) |
| "A meta-analysis found higher rates of seizure cessation with valproate 75." | 2.53 | Pharmacologic treatment of status epilepticus. ( Brigo, F; Höfler, J; Kalss, G; Leitinger, M; Rohracher, A; Trinka, E, 2016) |
| "Valnoctamide has a stereoselective PK with (2S,3S)-VCD exhibiting the lowest clearance and, consequently, a twice-higher plasma exposure than all other stereoisomers." | 2.52 | The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. ( Bialer, M; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Yagen, B, 2015) |
| " Safety studies of intravenous VPA administration in patients with SE showed a low incidence of adverse events overall (<10%), mainly dizziness, thrombocytopenia, and mild hypotension, which was independent of infusion rates." | 2.50 | Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. ( Brigo, F; Höfler, J; Trinka, E; Zerbs, A, 2014) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| " For each class, the dosing scheme and practical issues related to administration are described, based on evidence when available in the literature." | 2.45 | [Drugs for status epilepticus treatment]. ( Mazoit, JX; Navarro, V, 2009) |
| "Status epilepticus is a neurologic emergency associated with high mortality and long-term disability." | 2.42 | New management strategies in the treatment of status epilepticus. ( Manno, EM, 2003) |
| "Epilepsy was controlled with valproate at the age of 6 years." | 2.42 | A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders. ( Fiore, LA; Freitas, A; Kim, CA; Valente, KD, 2003) |
| "Status epilepticus is a serious medical emergency that requires prompt and appropriate intervention." | 2.41 | Status epilepticus. ( Fiallos, MR; Hanhan, UA; Orlowski, JP, 2001) |
| "Nonconvulsive status epilepticus is being considered and recognized more often, including in ambulatory patients with a confusional state, after convulsive status epilepticus, and in critically ill patients." | 2.41 | The current state of treatment of status epilepticus. ( Claassen, J; Hirsch, LJ, 2002) |
| "Status epilepticus is an emergency situation that can often lead to death or neurocognitive deficits despite adequate therapy is conducted." | 2.41 | [Status epilepticus and its treatment]. ( Futó, J; Katalin, T, 2002) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| " New antiepileptic drugs have improved medical management, and technical and theoretical advances in pharmacokinetics have permitted physicians to design balanced dosing for individual patients." | 2.36 | Recent developments in the diagnosis and therapy of epilepsy. ( Crandall, PH; Engel, J; Sterman, MB; Troupin, AS; Wasterlain, CG, 1982) |
| "Valproate-induced encephalopathy (VIE) affects between 0." | 1.91 | Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment. ( Beuchat, I; Loser, V; Novy, J; Rossetti, AO, 2023) |
| "Idiopathic generalized epilepsy with phantom absences, absence status, and generalized tonic-clonic seizures is an extremely rare condition." | 1.91 | Idiopathic generalized epilepsy with phantom absences, absence status, and generalized tonic-clonic seizures: A case report. ( Jiang, Y; Zhou, X, 2023) |
| "Midazolam has become the preferred benzodiazepine in pre- and in-hospital settings, both in children and adults." | 1.91 | Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany. ( Czabanka, M; Kieslich, M; Merker, M; Purwien, L; Ronellenfitsch, MW; Rosenow, F; Schubert-Bast, S; Strzelczyk, A; Willems, LM, 2023) |
| " If confirmed in further studies, a dosage of 25-30 mg/kg appears adequate in SE." | 1.72 | Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response. ( André, P; Buclin, T; Decosterd, LA; Novy, J; Rossetti, AO; Vijiala, S, 2022) |
| "The patient had initial seizures during sleep at the age of 1 year, with the left mouth pouting, left eye blinking and drooling for several seconds, and, sometimes, the left upper-limb flexion and head version to the left, lasting for 1-2 min." | 1.51 | Acquired epileptiform opercular syndrome evaluated with real-time transcranial Doppler ultrasound-video-electroencephalogram before and after treatment: a case report. ( Chen, WX; Li, JL; Liang, HC; Liang, W; Peng, BW; Yang, SY; Zhang, FQ, 2019) |
| " Criterion 2=the last drug introduced into the antiepileptic therapy within 72h before the cessation of SE and without changes in dosage or number of the co-medication." | 1.46 | The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined? ( Redecker, J; Rösche, J; Wittstock, M, 2017) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 1.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| " Consequently, in the current study a comparative pharmacokinetic (PK)-pharmacodynamic analysis of SPD was conducted following i." | 1.43 | Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ( Bialer, M; Bibi, D; Blotnik, S; Mawasi, H; Shaul, C; Shekh-Ahmad, T, 2016) |
| "VPA) as first-line treatment of status epilepticus (SE) and seizure clusters in selected patient populations." | 1.40 | Clinical experience with intravenous valproate as first-line treatment of status epilepticus and seizure clusters in selected populations. ( Casciato, S; Di Bonaventura, C; Fanella, M; Fattouch, J; Giallonardo, AT; Gregori, B; Lapenta, L; Manfredi, M; Morano, A; Vanacore, N; Vaudano, AE, 2014) |
| " This study describes synthesis and stereospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmacokinetic (PK) analysis of four individual SPD stereoisomers." | 1.39 | Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. ( Bialer, M; Finnell, RH; Hen, N; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, B; Yagen, B, 2013) |
| "Pancytopenia was recovered after discontinuation of valproate but panhypogammaglobulinemia has been persisting." | 1.39 | Valproate-induced panhypogammaglobulinemia. ( Eom, TH; Jang, PS; Kim, YH; Lee, HS, 2013) |
| "Pentobarbital was chosen later in the therapy for all ages." | 1.39 | Treatment of status epilepticus: an international survey of experts. ( Alldredge, B; Bell, R; Bleck, TP; Brophy, GM; Claassen, J; Glauser, T; LaRoche, SM; Riviello, JJ; Shutter, L; Sperling, MR; Treiman, DM; Vespa, PM, 2013) |
| "Better treatment of status epilepticus (SE), which typically becomes refractory after about 30 min, will require new pharmacotherapies." | 1.39 | A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. ( Bialer, M; Dudek, FE; Hen, N; Kaufmann, D; Nelson, C; Pouliot, W; Ricks, K; Roach, B; Shekh-Ahmad, T; Yagen, B, 2013) |
| "The activity of these compounds on seizure control is independent of histone deacetylase inhibitory activity (associated with the teratogenicity of VPA), and does not correlate with liver cell toxicity." | 1.39 | Seizure control by ketogenic diet-associated medium chain fatty acids. ( Chang, P; Chen, PE; Plant, N; Terbach, N; Walker, MC; Williams, RS, 2013) |
| "Phenytoin was used in 56 patients (22%) with the majority (n= 43) receiving intravenous phenytoin." | 1.38 | Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change? ( Bergin, P; Jones, P; Rosemergy, I; Walker, E, 2012) |
| " Pharmacokinetic parameters are necessary to predict the optimum therapeutic level after administration." | 1.37 | Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ( Bhudhisawadi, K; Chulavatnatol, S; Kaojareon, S; Vaewpanich, J; Visudtibhan, A, 2011) |
| "Status epilepticus is a common neurological emergency in childhood and associated with significant morbidity and mortality." | 1.37 | Status epilepticus. ( Gulati, S; Lodha, R; Raj, D, 2011) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| "The valproic acid plasma level was very high (1437 μg/mL), confirming it was a severe intoxication." | 1.37 | [Acute valproic acid intoxication: interest of a treatment by extracoporeal elimination combined with L-carnitine]. ( Alluin, A; Canevet, C; Desmaretz, JL; Gauthier, N; Jezequel, J, 2011) |
| "The hypotension was treated initially with intravenous fluid hydration with normal saline, but the blood pressure correction was transient using this approach." | 1.36 | Probable valproate sodium-associated hypotension. ( Ota, KS, 2010) |
| "Absence status was aggravated with carbamazepine and generalised tonic-clonic seizures were not controlled with ethosuximide." | 1.36 | Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status. ( Genton, P; Velizarova, R, 2010) |
| "Of patients with status epilepticus and central nervous system infection, 24." | 1.35 | Status epilepticus in central nervous system infections: an experience from a developing country. ( Kalita, J; Misra, UK; Nair, PP, 2008) |
| "A diagnosis of generalized NCSE with tonic seizures was made on the basis of the clinical picture and response to barbiturate anaesthetic, although the EEG pattern was not typical of the changes previously described in tonic seizures-tonic status epilepticus." | 1.33 | Prolonged postictal stupor: nonconvulsive status epilepticus, medication effect, or postictal state? ( Chattopadhyay, A; Kuc, S; Langheinrich, TC; Reuber, M, 2005) |
| "Nonconvulsive status epilepticus is characterized by continuous or near continuous epileptiform discharges on electroencephalography without overt motor or sensory phenomena." | 1.33 | Nonconvulsive status epilepticus and neurodevelopmental delay. ( Dirik, E; Hüdaoglu, O; Kurul, S; Yiş, U, 2006) |
| "Intravenous VPA loading is safe and effective for treating acute seizure emergencies in children." | 1.32 | Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. ( Cunanan, C; Mills, S; Thompson, N; Yu, KT, 2003) |
| "A young woman with juvenile myoclonic epilepsy had recurrent attacks of myoclonic status epilepticus related to a long history of limited compliance and irregular sleep." | 1.31 | Myoclonic status epilepticus: video presentation. ( Andermann, E; Andermann, F; Badhwar, A; Siren, A, 2002) |
| "Three patients aged 16, 19, and 65 years with a 13- to 36-year history of partial epilepsy were receiving a therapeutic dosage of carbamazepine or phenobarbital plus either clobazam (CLB) or valproate (VPA)." | 1.30 | Negative myoclonic status due to antiepileptic drug tapering: report of three cases. ( Aguglia, U; Gambardella, A; Oliveri, RL; Quattrone, A; Russo, C; Zappia, M, 1997) |
| " Poor compliance may contribute to the occurrence of status epilepticus, resulting in the need for substantial increases in anticonvulsant dosing to suppress seizures." | 1.30 | Status epilepticus during pregnancy. A case report. ( Licht, EA; Sankar, R, 1999) |
| " To provide loading and maintenance dosing for patients with hepatic induction secondary to concurrent anticonvulsants." | 1.30 | Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ( Chicella, MF; Dalton, JT; Eades, SK; Hovinga, CA; Phelps, SJ; Rose, DF, 1999) |
| "When phenytoin was discontinued, valproate levels increased, and he progressively improved." | 1.30 | Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999) |
| "Here a case of hemorrhagic shock and fulminant hepatic failure in a patient treated with valproate is presented." | 1.29 | [Hemorrhagic shock and fulminant hepatic failure associated with valproate]. ( Fernandez-Fernandez, FJ; Garcia-Jimenez, A; Garcia-Rego, J; Sesma, P, 1995) |
| " Depending on its pharmacokinetic parameters, each drug effect has a different onset, intensity, and time course." | 1.27 | Clinical pharmacokinetics of drugs used in the treatment of status epilepticus. ( Baars, AM; van der Dries, A; van der Kleijn, E; Vree, TB, 1983) |
| "Only when the epilepsy is uncontrolled despite high plasma concentrations which cannot be raised because of side effects, a second drug should be given." | 1.27 | [Pharmacotherapy of epilepsy--current problems and controversies]. ( Schmidt, D, 1983) |
| "Children with seizure disorders frequently are treated with anticonvulsant medications such as clonazepam, valproic acid, carbamazepine, and ethosuximide, which cannot be given parenterally." | 1.27 | Rectal anticonvulsants in pediatric practice. ( Laney, SM; Woody, RC, 1988) |
| "This work shows that, for the treatment of status epilepticus, a loading dose of valproate by oral or rectal way is therapeutically equivalent to diazepam and clobazam." | 1.27 | [Treatment of status epilepticus by sodium valproate]. ( Dumas, R; Giroud, M, 1988) |
| " In two patients, the route of administration was changed from rectal to an equivalent oral dose with continuing control of seizures and minimal change in plasma levels, suggesting that bioavailability is similar for the two forms of the drug." | 1.26 | Rectal administration of sodium valproate in status epilepticus. ( Bladin, PF; Donnan, GA; Mihaly, GW; Miles, JL; Vajda, FJ, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (13.16) | 18.7374 |
| 1990's | 28 (10.53) | 18.2507 |
| 2000's | 68 (25.56) | 29.6817 |
| 2010's | 93 (34.96) | 24.3611 |
| 2020's | 42 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Hen, N | 6 |
| Bialer, M | 9 |
| Yagen, B | 7 |
| Su, Y | 3 |
| Huang, H | 2 |
| Jiang, M | 3 |
| Pan, S | 1 |
| Ding, L | 1 |
| Zhang, L | 1 |
| Jiang, W | 2 |
| Zhuang, X | 1 |
| Abbaskhanian, A | 1 |
| Sheidaee, K | 1 |
| Charati, JY | 1 |
| Singh, S | 2 |
| Singh, TG | 2 |
| Singh, M | 1 |
| Najda, A | 1 |
| Nurzyńska-Wierdak, R | 1 |
| Almeer, R | 1 |
| Kamel, M | 1 |
| Abdel-Daim, MM | 1 |
| Melikishvili, G | 1 |
| Bienvenu, T | 1 |
| Tabatadze, N | 1 |
| Gachechiladze, T | 1 |
| Kurua, E | 1 |
| Gverdtsiteli, S | 1 |
| Melikishvili, M | 1 |
| Dulac, O | 1 |
| Roberti, R | 1 |
| Rocca, M | 1 |
| Iannone, LF | 1 |
| Gasparini, S | 1 |
| Pascarella, A | 1 |
| Neri, S | 1 |
| Cianci, V | 1 |
| Bilo, L | 1 |
| Russo, E | 1 |
| Quaresima, P | 1 |
| Aguglia, U | 2 |
| Di Carlo, C | 1 |
| Ferlazzo, E | 2 |
| Vijiala, S | 1 |
| André, P | 1 |
| Buclin, T | 1 |
| Decosterd, LA | 1 |
| Rossetti, AO | 5 |
| Novy, J | 2 |
| Coralic, Z | 1 |
| Kapur, J | 7 |
| Olson, KR | 1 |
| Chamberlain, JM | 6 |
| Overbeek, D | 1 |
| Silbergleit, R | 8 |
| Kandeda, AK | 1 |
| Nodeina, S | 1 |
| Mabou, ST | 1 |
| Zou, X | 1 |
| Zhu, Z | 1 |
| Guo, Y | 1 |
| Zhang, H | 1 |
| Liu, Y | 1 |
| Cui, Z | 1 |
| Ke, Z | 1 |
| Jiang, S | 1 |
| Tong, Y | 1 |
| Wu, Z | 1 |
| Mao, Y | 1 |
| Chen, L | 2 |
| Wang, D | 1 |
| Sager, SG | 1 |
| Turkyilmaz, A | 1 |
| Gunbey, HP | 1 |
| Karatoprak, EY | 1 |
| Aslan, ES | 1 |
| Akın, Y | 1 |
| Jain, P | 1 |
| Aneja, S | 1 |
| Cunningham, J | 1 |
| Arya, R | 1 |
| Sharma, S | 1 |
| Soto-Insuga, V | 1 |
| González-Alguacil, E | 1 |
| García-Peñas, JJ | 1 |
| Maghbooli, M | 2 |
| Jourahmad, Z | 2 |
| Golizadeh, M | 2 |
| Buratti, S | 1 |
| Giacheri, E | 1 |
| Palmieri, A | 1 |
| Tibaldi, J | 1 |
| Brisca, G | 1 |
| Riva, A | 1 |
| Striano, P | 3 |
| Mancardi, MM | 1 |
| Nobili, L | 1 |
| Moscatelli, A | 1 |
| Zhang, X | 1 |
| Yi, Y | 1 |
| Cheng, L | 1 |
| Chen, H | 1 |
| Hu, Y | 2 |
| Loser, V | 1 |
| Beuchat, I | 1 |
| Liu, G | 2 |
| Wang, Y | 2 |
| Tian, F | 2 |
| Chen, W | 2 |
| Zhang, Y | 3 |
| Jiang, Y | 1 |
| Zhou, X | 1 |
| Purwien, L | 1 |
| Schubert-Bast, S | 1 |
| Kieslich, M | 1 |
| Ronellenfitsch, MW | 1 |
| Merker, M | 1 |
| Czabanka, M | 1 |
| Willems, LM | 1 |
| Rosenow, F | 3 |
| Strzelczyk, A | 1 |
| Niquet, J | 4 |
| Lumley, L | 4 |
| Baldwin, R | 4 |
| Rossetti, F | 2 |
| Suchomelova, L | 4 |
| Naylor, D | 2 |
| Estrada, IBF | 1 |
| Schultz, M | 2 |
| Furtado, MA | 1 |
| Wasterlain, CG | 5 |
| de Araujo Furtado, M | 1 |
| Franco-Estrada, I | 1 |
| Cock, HR | 4 |
| Coles, LD | 3 |
| Elm, J | 5 |
| Cloyd, JC | 3 |
| Fountain, N | 3 |
| Shinnar, S | 6 |
| Lowenstein, D | 4 |
| Conwit, R | 3 |
| Bleck, TP | 6 |
| Barsan, W | 2 |
| Cloyd, J | 3 |
| Meinzer, C | 2 |
| Cock, H | 3 |
| Connor, JT | 3 |
| Pepi, C | 1 |
| Cesaroni, E | 2 |
| Maiorani, D | 1 |
| Pruna, D | 1 |
| Cossu, S | 1 |
| Di Capua, M | 1 |
| Vigevano, F | 4 |
| Specchio, N | 2 |
| Cusmai, R | 1 |
| Reindl, C | 1 |
| Sprügel, MI | 1 |
| Sembill, JA | 1 |
| Mueller, TM | 1 |
| Hagen, M | 1 |
| Gerner, ST | 1 |
| Kuramatsu, JB | 1 |
| Hamer, HM | 1 |
| Huttner, HB | 1 |
| Madžar, D | 1 |
| Liampas, I | 1 |
| Siokas, V | 1 |
| Brotis, A | 1 |
| Zintzaras, E | 1 |
| Stefanidis, I | 1 |
| Dardiotis, E | 1 |
| Pietrafusa, N | 1 |
| Ferretti, A | 1 |
| Trivisano, M | 1 |
| McCarren, HS | 1 |
| Eisen, MR | 1 |
| Nguyen, DL | 1 |
| Dubée, PB | 1 |
| Ardinger, CE | 1 |
| Dunn, EN | 1 |
| Haines, KM | 1 |
| Santoro, AN | 1 |
| Bodner, PM | 1 |
| Ondeck, CA | 1 |
| Honnold, CL | 1 |
| McDonough, JH | 6 |
| Beske, PH | 1 |
| McNutt, PM | 1 |
| Deng, L | 1 |
| Ma, A | 1 |
| Wood, N | 1 |
| Ardern-Holmes, S | 1 |
| Kunju, PAM | 1 |
| Subir, HA | 1 |
| Vignesh, V | 1 |
| Rameshkumar, R | 1 |
| Mahadevan, S | 1 |
| Appleton, RE | 1 |
| Holsti, M | 1 |
| Babcock, L | 2 |
| Rogers, A | 1 |
| Fountain, NB | 3 |
| Underwood, E | 1 |
| Sathe, AG | 2 |
| Elm, JJ | 3 |
| Lowenstein, DH | 3 |
| Conwit, RA | 1 |
| Wu, K | 1 |
| Hirsch, LJ | 2 |
| Babl, FE | 1 |
| Josephson, SA | 1 |
| Habhab, SF | 1 |
| Ulvin, LB | 1 |
| Taubøll, E | 2 |
| Svalheim, S | 1 |
| Olsen, KB | 2 |
| Horn, MA | 1 |
| Heuser, K | 1 |
| Samanta, D | 1 |
| Fisch, U | 1 |
| Baumann, SM | 1 |
| Semmlack, S | 1 |
| Marsch, S | 1 |
| Rüegg, S | 1 |
| Sutter, R | 1 |
| Müller, A | 1 |
| Schmiedeknecht, A | 1 |
| Mende, M | 1 |
| Awissus, C | 1 |
| Hamer, H | 1 |
| Classen, J | 1 |
| Mishra, U | 1 |
| Ivaturi, V | 1 |
| Brundage, RC | 1 |
| Gore, A | 1 |
| Neufeld-Cohen, A | 1 |
| Egoz, I | 1 |
| Baranes, S | 1 |
| Gez, R | 1 |
| Efrati, R | 1 |
| David, T | 1 |
| Dekel Jaoui, H | 1 |
| Yampolsky, M | 1 |
| Grauer, E | 1 |
| Chapman, S | 1 |
| Lazar, S | 1 |
| Smith, KM | 1 |
| Britton, JW | 1 |
| Hocker, SE | 1 |
| Toledano, M | 1 |
| Beddoes, P | 1 |
| Nerone, G | 1 |
| Tai, C | 1 |
| Wabl, R | 1 |
| Terman, SW | 1 |
| Kwok, M | 1 |
| Chamberlain, J | 2 |
| Hill, CE | 1 |
| Redecker, J | 1 |
| Wittstock, M | 1 |
| Rösche, J | 2 |
| Norman, K | 2 |
| Verrotti, A | 2 |
| Ambrosi, M | 1 |
| Pavone, P | 1 |
| Misra, UK | 4 |
| Dubey, D | 1 |
| Kalita, J | 4 |
| Gillinder, L | 1 |
| Lehn, A | 1 |
| Brown, H | 1 |
| Dionisio, S | 1 |
| Amiri-Nikpour, MR | 1 |
| Nazarbaghi, S | 1 |
| Eftekhari, P | 1 |
| Mohammadi, S | 1 |
| Dindarian, S | 1 |
| Bagheri, M | 1 |
| Mohammadi, H | 1 |
| Janszky, J | 1 |
| Tényi, D | 1 |
| Bóné, B | 1 |
| Ran, X | 1 |
| Xiang, J | 1 |
| Song, PP | 1 |
| Jiang, L | 1 |
| Liu, BK | 1 |
| Zhou, C | 1 |
| Sui, Y | 1 |
| Zhao, W | 1 |
| Dong, C | 1 |
| Ren, L | 1 |
| Song, P | 1 |
| Xu, B | 1 |
| Sun, X | 1 |
| Sands, TT | 1 |
| Rahdari, S | 1 |
| Oldham, MS | 1 |
| Caminha Nunes, E | 1 |
| Tilton, N | 1 |
| Cilio, MR | 1 |
| Caraballo, RH | 1 |
| Chacón, S | 1 |
| Fasulo, L | 1 |
| Bedoya, C | 1 |
| Romoli, M | 1 |
| Mazzocchetti, P | 1 |
| D'Alonzo, R | 1 |
| Siliquini, S | 1 |
| Rinaldi, VE | 1 |
| Calabresi, P | 2 |
| Costa, C | 1 |
| Nene, D | 1 |
| Mundlamuri, RC | 2 |
| Satishchandra, P | 2 |
| Prathyusha, PV | 2 |
| Nagappa, M | 2 |
| Bindu, PS | 2 |
| Raghavendra, K | 1 |
| Saini, J | 1 |
| Bharath, RD | 1 |
| Thennarasu, K | 1 |
| Taly, AB | 2 |
| Sinha, S | 3 |
| Nandal, S | 1 |
| Castles, A | 1 |
| Asrar Ul Haq, M | 1 |
| van Gaal, W | 1 |
| Watkins, LV | 1 |
| Angus-Leppan, H | 1 |
| Shankar, R | 1 |
| Lind, J | 1 |
| Nordlund, P | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Sánchez Fernández, I | 1 |
| Gaínza-Lein, M | 1 |
| Lamb, N | 1 |
| Loddenkemper, T | 1 |
| Itoh, K | 1 |
| Taniguchi, R | 1 |
| Matsuo, T | 1 |
| Oguro, A | 1 |
| Vogel, CFA | 1 |
| Yamazaki, T | 1 |
| Ishihara, Y | 1 |
| Peng, BW | 1 |
| Liang, HC | 1 |
| Li, JL | 1 |
| Yang, SY | 1 |
| Liang, W | 1 |
| Zhang, FQ | 1 |
| Chen, WX | 1 |
| Viloria Alebesque, A | 1 |
| Montes Castro, N | 1 |
| Arcos Sánchez, C | 1 |
| Vicente Gordo, D | 1 |
| Imran, I | 1 |
| Koch, K | 1 |
| Schöfer, H | 1 |
| Lau, H | 1 |
| Klein, J | 1 |
| Lee, DS | 1 |
| Ryu, HJ | 1 |
| Kim, JE | 2 |
| Choi, HC | 2 |
| Kim, YI | 2 |
| Song, HK | 2 |
| Kang, TC | 2 |
| Hilly-Ginoux, J | 1 |
| Merceron, S | 1 |
| Pinoteau, J | 1 |
| Palette, C | 1 |
| Bedos, JP | 1 |
| Legriel, S | 1 |
| Lapenta, L | 1 |
| Morano, A | 1 |
| Casciato, S | 1 |
| Fanella, M | 1 |
| Fattouch, J | 1 |
| Vaudano, AE | 1 |
| Gregori, B | 1 |
| Vanacore, N | 1 |
| Manfredi, M | 1 |
| Giallonardo, AT | 1 |
| Di Bonaventura, C | 1 |
| Broglio, KR | 1 |
| Shekh-Ahmad, T | 8 |
| Finnell, RH | 2 |
| Wlodarczyk, B | 1 |
| Brigo, F | 5 |
| Igwe, SC | 1 |
| Nardone, R | 2 |
| Tezzon, F | 1 |
| Bongiovanni, LG | 2 |
| Trinka, E | 9 |
| Bleck, T | 1 |
| Connor, J | 1 |
| Jones, E | 1 |
| Treiman, D | 1 |
| Chang, P | 3 |
| Walker, MC | 4 |
| Williams, RS | 3 |
| Wlodarczyk, BJ | 1 |
| Une, H | 1 |
| Uehara, T | 1 |
| Tateishi, T | 1 |
| Shigetou, H | 1 |
| Oyagi, Y | 1 |
| Kira, J | 1 |
| Höfler, J | 2 |
| Zerbs, A | 1 |
| Grosso, S | 1 |
| Zamponi, N | 1 |
| Bartocci, A | 1 |
| Cappanera, S | 1 |
| Di Bartolo, R | 1 |
| Balestri, P | 1 |
| Wei, D | 1 |
| Yang, F | 2 |
| Wu, C | 1 |
| Wu, SX | 1 |
| Bar-Klein, G | 1 |
| Swissa, E | 1 |
| Kamintsky, L | 1 |
| Saar-Ashkenazy, R | 1 |
| Hubary, Y | 1 |
| Shrot, S | 1 |
| Stetlander, L | 1 |
| Eisenkraft, A | 1 |
| Friedman, A | 1 |
| Gélisse, P | 1 |
| Crespel, A | 1 |
| Inoue, S | 1 |
| Yazawa, S | 1 |
| Murahara, T | 1 |
| Yamauchi, R | 1 |
| Shimohama, S | 1 |
| Mawasi, H | 2 |
| Özdemir, HH | 1 |
| Müngen, B | 1 |
| İlhan, S | 1 |
| Subbakrishna, DK | 1 |
| Umamaheswara Rao, GS | 1 |
| Lusardi, TA | 1 |
| Akula, KK | 1 |
| Coffman, SQ | 1 |
| Ruskin, DN | 1 |
| Masino, SA | 1 |
| Boison, D | 1 |
| Karlov, VA | 2 |
| Vlasov, PN | 1 |
| Gladov, BP | 1 |
| Kamelkova, EG | 1 |
| Leitinger, M | 1 |
| Rohracher, A | 1 |
| Kalss, G | 1 |
| Paschen, I | 1 |
| Walter, U | 1 |
| Kamm, C | 1 |
| Töllner, K | 1 |
| Twele, F | 1 |
| Löscher, W | 2 |
| Grande-Martín, A | 1 |
| Pardal-Fernández, JM | 1 |
| Carrascosa-Romero, MC | 1 |
| De Cabo, C | 1 |
| İşgüder, R | 1 |
| Güzel, O | 1 |
| Ceylan, G | 1 |
| Yılmaz, Ü | 1 |
| Ağın, H | 1 |
| Bibi, D | 1 |
| Shaul, C | 1 |
| Blotnik, S | 1 |
| Tomson, T | 1 |
| Battino, D | 1 |
| Bonizzoni, E | 1 |
| Craig, J | 1 |
| Lindhout, D | 1 |
| Perucca, E | 2 |
| Sabers, A | 1 |
| Thomas, SV | 1 |
| Vajda, F | 1 |
| Bragazzi, N | 1 |
| Ren, G | 1 |
| Chun, B | 1 |
| Ye, H | 1 |
| Gao, D | 1 |
| Fung, EL | 1 |
| Fung, BB | 1 |
| Nair, PP | 1 |
| Gilad, R | 1 |
| Izkovitz, N | 1 |
| Dabby, R | 1 |
| Rapoport, A | 1 |
| Sadeh, M | 1 |
| Weller, B | 1 |
| Lampl, Y | 1 |
| Wheless, JW | 3 |
| Treiman, DM | 3 |
| Navarro, V | 1 |
| Mazoit, JX | 1 |
| Feng, P | 1 |
| Wang, J | 1 |
| Liu, L | 1 |
| Zhou, D | 1 |
| García, C | 1 |
| Rubio, G | 1 |
| van Vliet, EA | 1 |
| Edelbroek, PM | 1 |
| Gorter, JA | 1 |
| Lagae, L | 1 |
| Tiamkao, S | 1 |
| Sawanyawisuth, K | 1 |
| Tripathi, M | 1 |
| Vibha, D | 1 |
| Choudhary, N | 1 |
| Prasad, K | 1 |
| Srivastava, MV | 1 |
| Bhatia, R | 1 |
| Chandra, SP | 1 |
| Visudtibhan, A | 1 |
| Bhudhisawadi, K | 1 |
| Vaewpanich, J | 1 |
| Chulavatnatol, S | 1 |
| Kaojareon, S | 1 |
| Liukkonen, E | 1 |
| Kantola-Sorsa, E | 1 |
| Paetau, R | 1 |
| Gaily, E | 2 |
| Peltola, M | 1 |
| Granström, ML | 1 |
| Ota, KS | 1 |
| Linnet, KM | 1 |
| Kragh-Olsen, B | 1 |
| Kwan, SY | 1 |
| Kholin, AA | 2 |
| Il'ina, ES | 1 |
| Lemeshko, ID | 1 |
| Mukhin, KIu | 1 |
| Petrukhin, AS | 2 |
| Voronkova, KV | 1 |
| Pylaeva, OA | 1 |
| Hessen, E | 1 |
| Lossius, MI | 1 |
| Gjerstad, L | 2 |
| Velizarova, R | 1 |
| Genton, P | 2 |
| Raj, D | 1 |
| Gulati, S | 1 |
| Lodha, R | 1 |
| Andreeva, OV | 1 |
| LaRoche, SM | 2 |
| Shivdat-Nanhoe, R | 1 |
| Alvarez, V | 1 |
| Januel, JM | 1 |
| Burnand, B | 1 |
| Chen, WB | 1 |
| Gao, R | 1 |
| Su, YY | 1 |
| Zhao, JW | 1 |
| Zhang, YZ | 1 |
| Wang, L | 1 |
| Ren, Y | 1 |
| Fan, CQ | 1 |
| Alluin, A | 1 |
| Jezequel, J | 1 |
| Gauthier, N | 1 |
| Desmaretz, JL | 1 |
| Canevet, C | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 2 |
| Singhi, P | 2 |
| White, HS | 1 |
| Alex, AB | 1 |
| Pollock, A | 1 |
| Wilcox, KS | 1 |
| Stables, JP | 1 |
| Kaufmann, D | 2 |
| Storti, M | 1 |
| Del Felice, A | 1 |
| Fiaschi, A | 1 |
| Liu, X | 1 |
| Wu, Y | 1 |
| Chen, Z | 1 |
| Ma, M | 1 |
| Su, L | 1 |
| Malamiri, RA | 1 |
| Ghaempanah, M | 1 |
| Khosroshahi, N | 1 |
| Nikkhah, A | 1 |
| Bavarian, B | 1 |
| Ashrafi, MR | 1 |
| Pittermann, P | 1 |
| Gabriel, S | 1 |
| Röschke, J | 1 |
| Rosemergy, I | 1 |
| Bergin, P | 1 |
| Jones, P | 1 |
| Walker, E | 1 |
| Galimi, R | 1 |
| Eom, TH | 1 |
| Lee, HS | 1 |
| Jang, PS | 1 |
| Kim, YH | 1 |
| Kaplan, PW | 3 |
| Schlattman, DK | 1 |
| Riviello, JJ | 1 |
| Claassen, J | 2 |
| Sperling, MR | 1 |
| Alldredge, B | 1 |
| Glauser, T | 1 |
| Shutter, L | 1 |
| Vespa, PM | 1 |
| Bell, R | 1 |
| Brophy, GM | 1 |
| Ermolenko, NA | 1 |
| Ermakov, AIu | 1 |
| Buchneva, IA | 1 |
| Zakharova, EI | 1 |
| Kalikina, TA | 1 |
| Pouliot, W | 1 |
| Ricks, K | 1 |
| Roach, B | 1 |
| Nelson, C | 1 |
| Dudek, FE | 1 |
| Terbach, N | 1 |
| Plant, N | 1 |
| Chen, PE | 1 |
| Dilitz, E | 1 |
| Unterberger, I | 1 |
| Luef, G | 1 |
| Deisenhammer, F | 1 |
| Niedermüller, U | 1 |
| Thaler, C | 1 |
| Bauer, G | 1 |
| Arzimanoglou, A | 2 |
| Baulac, M | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Manno, EM | 1 |
| Yoshimura, K | 1 |
| Yu, KT | 1 |
| Mills, S | 1 |
| Thompson, N | 1 |
| Cunanan, C | 1 |
| Valente, KD | 1 |
| Freitas, A | 1 |
| Fiore, LA | 1 |
| Kim, CA | 1 |
| Burneo, JG | 2 |
| Limdi, N | 1 |
| Kuzniecky, RI | 1 |
| Knowlton, RC | 1 |
| Mendez, M | 1 |
| Lawn, N | 1 |
| Faught, E | 2 |
| Welty, TE | 1 |
| Prasad, A | 1 |
| Heckmann, JG | 1 |
| Lang, CJ | 1 |
| Stefan, H | 1 |
| Neundörfer, B | 1 |
| Toomes, M | 1 |
| Maleck, WH | 1 |
| Koetter, KP | 1 |
| Petroianu, GA | 1 |
| Martín, ED | 1 |
| Pozo, MA | 1 |
| Jha, S | 2 |
| Jose, M | 1 |
| Patel, R | 3 |
| Vazquez, BR | 1 |
| Kanner, AM | 1 |
| Ramsay, RE | 2 |
| Morton, L | 1 |
| Pellock, JM | 1 |
| Limdi, NA | 1 |
| Shimpi, AV | 1 |
| Gomez, CR | 1 |
| Scholtes, FB | 1 |
| Hendriks, MP | 1 |
| Renier, WO | 1 |
| Penovich, P | 1 |
| Peters, CN | 1 |
| Pohlmann-Eden, B | 1 |
| Martella, G | 1 |
| De Persis, C | 1 |
| Bonsi, P | 1 |
| Natoli, S | 1 |
| Cuomo, D | 1 |
| Bernardi, G | 1 |
| Pisani, A | 1 |
| Bromfield, EB | 1 |
| Riggio, S | 1 |
| Langheinrich, TC | 1 |
| Chattopadhyay, A | 1 |
| Kuc, S | 1 |
| Reuber, M | 1 |
| Tucker, A | 1 |
| Miyake, H | 1 |
| Tsuji, M | 1 |
| Ukita, T | 1 |
| Nishihara, K | 1 |
| Aldenkamp, A | 1 |
| Covanis, A | 1 |
| Brandt, C | 1 |
| Gastens, AM | 1 |
| Sun, Mz | 1 |
| Hausknecht, M | 1 |
| Dirik, E | 1 |
| Yiş, U | 1 |
| Hüdaoglu, O | 1 |
| Kurul, S | 1 |
| Embacher, N | 1 |
| Karner, E | 1 |
| Wanschitz, J | 1 |
| Beer, R | 1 |
| Spriet, I | 1 |
| Meersseman, W | 1 |
| De Troy, E | 1 |
| Wilmer, A | 1 |
| Casteels, M | 1 |
| Willems, L | 1 |
| Ivanov, I | 1 |
| Klein, M | 1 |
| Green, WH | 1 |
| Coffey, B | 1 |
| Minicucci, F | 1 |
| Muscas, G | 1 |
| Capovilla, G | 1 |
| Tinuper, P | 1 |
| Narayanan, JT | 1 |
| Murthy, JM | 1 |
| Kim, DS | 1 |
| Kwak, SE | 1 |
| Choi, SY | 1 |
| Kwon, OS | 1 |
| Agarwal, P | 1 |
| Kumar, N | 1 |
| Chandra, R | 1 |
| Gupta, G | 1 |
| Antony, AR | 1 |
| Garg, N | 1 |
| Velioğlu, SK | 1 |
| Gazioğlu, S | 1 |
| Mehta, V | 1 |
| Thomas, P | 1 |
| Fernández, EA | 1 |
| González, CG | 1 |
| Pardillo, JC | 1 |
| García, VM | 1 |
| Delima, SI | 1 |
| Walsh, LE | 1 |
| Golomb, MR | 1 |
| Dardis, C | 1 |
| Farid, S | 1 |
| Doherty, C | 1 |
| Meldrum, B | 1 |
| Lockard, JS | 1 |
| Levy, RH | 1 |
| Koch, KM | 1 |
| Maris, DO | 1 |
| Friel, PN | 1 |
| van der Kleijn, E | 1 |
| Baars, AM | 1 |
| Vree, TB | 1 |
| van der Dries, A | 1 |
| Vajda, FJ | 3 |
| Somerville, ER | 1 |
| Bruni, J | 1 |
| Kakigi, R | 1 |
| Kuroda, Y | 1 |
| Shibasaki, H | 1 |
| Totoki, T | 1 |
| Sugimoto, T | 1 |
| Nishida, N | 1 |
| Yasuhara, A | 1 |
| Ono, A | 1 |
| Sakane, Y | 1 |
| Matsumura, T | 1 |
| Schmidt, D | 1 |
| Mancall, EL | 1 |
| Covington, TR | 1 |
| Alonso, RJ | 1 |
| Berkovic, SF | 1 |
| Bladin, PF | 3 |
| Viani, F | 1 |
| Jussi, MI | 1 |
| Germano, M | 1 |
| Lotti, P | 1 |
| Lotti, F | 1 |
| Beran, RG | 1 |
| Koch, H | 1 |
| Franke, D | 1 |
| Thorpy, MJ | 1 |
| Fröscher, W | 1 |
| Johnston, MV | 1 |
| Freeman, JM | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Philbert, A | 1 |
| Dam, M | 1 |
| Engel, J | 1 |
| Troupin, AS | 1 |
| Crandall, PH | 1 |
| Sterman, MB | 1 |
| Buchanan, N | 1 |
| Steinhoff, BJ | 1 |
| Stodieck, SR | 1 |
| Fernandez-Fernandez, FJ | 1 |
| Garcia-Rego, J | 1 |
| Garcia-Jimenez, A | 1 |
| Sesma, P | 1 |
| George, B | 1 |
| Kulkarni, SK | 1 |
| Holle, LM | 1 |
| Gidal, BE | 2 |
| Collins, DM | 1 |
| Parra, J | 1 |
| Iriarte, J | 1 |
| Pierre-Louis, SJ | 1 |
| DeToledo, JC | 1 |
| Haddad, H | 1 |
| Bauer, J | 1 |
| Helmstaedter, C | 1 |
| Elger, CE | 1 |
| Sonnen, AE | 1 |
| Thibodeau, LG | 1 |
| Ferrera, PC | 1 |
| Gambardella, A | 1 |
| Oliveri, RL | 1 |
| Russo, C | 1 |
| Zappia, M | 1 |
| Quattrone, A | 1 |
| Vaquerizo, J | 1 |
| Romero-Rodríguez, JC | 1 |
| González-Roncero, A | 1 |
| Gómez-Marcos, A | 1 |
| Bolanos, AR | 1 |
| Sarkisian, M | 1 |
| Yang, Y | 1 |
| Hori, A | 1 |
| Helmers, SL | 1 |
| Mikati, M | 1 |
| Tandon, P | 1 |
| Stafstrom, CE | 1 |
| Holmes, GL | 1 |
| Capocchi, G | 1 |
| Balducci, A | 1 |
| Cecconi, M | 1 |
| Pelli, MA | 1 |
| Picchiarelli, A | 1 |
| Silvestrelli, G | 1 |
| Zampolini, M | 1 |
| Corkill, RG | 1 |
| Hardie, RJ | 1 |
| Licht, EA | 1 |
| Sankar, R | 1 |
| Chez, MG | 1 |
| Hammer, MS | 1 |
| Loeffel, M | 1 |
| Nowinski, C | 1 |
| Bagan, BT | 1 |
| Hovinga, CA | 1 |
| Chicella, MF | 1 |
| Rose, DF | 1 |
| Eades, SK | 1 |
| Dalton, JT | 1 |
| Phelps, SJ | 1 |
| White, JR | 1 |
| Santos, CS | 1 |
| Norton, JW | 1 |
| Quarles, E | 1 |
| Begemann, M | 1 |
| Rowan, AJ | 1 |
| Tuhrim, S | 1 |
| Sheth, RD | 1 |
| Uberall, MA | 1 |
| Trollmann, R | 1 |
| Wunsiedler, U | 1 |
| Wenzel, D | 1 |
| D'Agostino, MD | 1 |
| Andermann, F | 2 |
| Dubeau, F | 1 |
| Fedi, M | 1 |
| Bastos, A | 1 |
| Yamamoto, LG | 1 |
| Yim, GK | 1 |
| Naritoku, DK | 1 |
| Roffe, C | 1 |
| Hanhan, UA | 1 |
| Fiallos, MR | 1 |
| Orlowski, JP | 1 |
| Hodges, BM | 1 |
| Mazur, JE | 1 |
| Badhwar, A | 1 |
| Siren, A | 1 |
| Andermann, E | 1 |
| Shahar, E | 1 |
| Andraus, J | 1 |
| Sagie-Lerman, T | 1 |
| Savitzki, D | 1 |
| Katalin, T | 1 |
| Futó, J | 1 |
| Symington, GR | 1 |
| Mihaly, GW | 1 |
| Miles, JL | 1 |
| Donnan, GA | 1 |
| Walton, NY | 1 |
| Bicknese, AR | 1 |
| May, W | 1 |
| Hickey, WF | 1 |
| Dodson, WE | 1 |
| Tanaka, T | 1 |
| Fujita, T | 1 |
| Tanaka, S | 1 |
| Takano, K | 1 |
| Yonemasu, Y | 1 |
| Sander, JW | 1 |
| Hart, YM | 1 |
| Trevisol-Bittencourt, PC | 1 |
| Kandrotas, RJ | 1 |
| Love, JM | 1 |
| Gal, P | 1 |
| Oles, KS | 1 |
| Gobbi, G | 1 |
| Bureau, M | 1 |
| Roger, J | 1 |
| Giovanardi-Rossi, P | 1 |
| Gram, L | 1 |
| Bentsen, KD | 1 |
| Wallace, SJ | 1 |
| Leppik, IE | 1 |
| Steinberg, A | 1 |
| Shalev, RS | 1 |
| Amir, N | 1 |
| Garcia de Alba, GO | 1 |
| Malagon Valdez, J | 1 |
| Franco Delgadillo, J | 1 |
| Ramos Peek, J | 1 |
| Woody, RC | 1 |
| Laney, SM | 1 |
| Giroud, M | 1 |
| Dumas, R | 1 |
| García García, MJ | 1 |
| López-Herce Cid, J | 1 |
| Martínez Bermejo, A | 1 |
| Perdikidi Olivieri, L | 1 |
| Rubio de la Iglesia, F | 1 |
| Hernández González, J | 1 |
| Snead, OC | 1 |
| Miles, MV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Efficacy of Combined Ketamine and Midazolam for Treatment of Generalized Convulsive Status Epilepticus in Children .[NCT05779657] | Phase 2/Phase 3 | 144 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| Localizing Functional Brain Cortices and Epileptogenic Zones With High Frequency Brain Signals[NCT00600717] | 420 participants (Anticipated) | Observational | 2000-11-01 | Enrolling by invitation | |||
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
53 reviews available for valproic acid and Absence Status
| Article | Year |
|---|---|
Status epilepticus in pregnancy: a literature review and a protocol proposal.
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Phenytoin; Pregnancy; Review Literature as Topic; St | 2022 |
Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Drug Resistance; Humans; Levetiracetam; Network Meta | 2022 |
[Paediatric status epilepticus].
Topics: Adult; Anesthetics; Anticonvulsants; Benzodiazepines; Child; Epilepsy; Humans; Ketamine; Lacosamide; | 2022 |
Refractory Convulsive Status Epilepticus Provoked by Intoxication with Dalfampridine in a Patient with Multiple Sclerosis and Depression Disorder: A Case Report and Literature Review.
Topics: 4-Aminopyridine; Adult; Epilepsy; Humans; Multiple Sclerosis; Sodium; Status Epilepticus; Valproic A | 2023 |
Refractory Convulsive Status Epilepticus Provoked by Intoxication with Dalfampridine in a Patient with Multiple Sclerosis and Depression Disorder: A Case Report and Literature Review.
Topics: 4-Aminopyridine; Adult; Epilepsy; Humans; Multiple Sclerosis; Sodium; Status Epilepticus; Valproic A | 2023 |
Refractory Convulsive Status Epilepticus Provoked by Intoxication with Dalfampridine in a Patient with Multiple Sclerosis and Depression Disorder: A Case Report and Literature Review.
Topics: 4-Aminopyridine; Adult; Epilepsy; Humans; Multiple Sclerosis; Sodium; Status Epilepticus; Valproic A | 2023 |
Refractory Convulsive Status Epilepticus Provoked by Intoxication with Dalfampridine in a Patient with Multiple Sclerosis and Depression Disorder: A Case Report and Literature Review.
Topics: 4-Aminopyridine; Adult; Epilepsy; Humans; Multiple Sclerosis; Sodium; Status Epilepticus; Valproic A | 2023 |
Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children.
Topics: Animals; Anticonvulsants; Benzodiazepines; Drug Resistant Epilepsy; Ketamine; Status Epilepticus; Va | 2023 |
Rational polytherapy in the treatment of cholinergic seizures.
Topics: Animals; Anticonvulsants; Cholinesterase Inhibitors; Drug Therapy, Combination; Ketamine; Male; Mida | 2020 |
Early polytherapy for benzodiazepine-refractory status epilepticus.
Topics: Animals; Anticonvulsants; Benzodiazepines; Drug Administration Schedule; Drug Resistant Epilepsy; Dr | 2019 |
Lessons from the Established Status Epilepticus Treatment Trial.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child, Preschool; Clinical Trials as Topic; Diagnostic Test | 2019 |
Intravenous sodium valproate in status epilepticus: review and Meta-analysis.
Topics: Administration, Intravenous; Anticonvulsants; Humans; Randomized Controlled Trials as Topic; Status | 2021 |
Epilepsy in Angelman syndrome: A scoping review.
Topics: Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Femal | 2021 |
Pediatric status epilepticus: improved management with new drug therapies?
Topics: Algorithms; Anticonvulsants; Child; Clinical Protocols; Humans; Ketamine; Levetiracetam; Midazolam; | 2017 |
[Valproate in the treatment of epilepsy and status epilepticus].
Topics: Anticonvulsants; Epilepsy; Humans; Status Epilepticus; Valproic Acid | 2017 |
The critical interaction between valproate sodium and warfarin: case report and review.
Topics: Aged; Anticoagulants; Anticonvulsants; Atrial Fibrillation; Drug Interactions; Female; Humans; Inter | 2018 |
Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences.
Topics: Animals; Anticonvulsants; Brain Injuries, Traumatic; Epilepsy; Histone Deacetylases; Humans; Neurons | 2019 |
Takotsubo cardiomyopathy triggered by status epilepticus: case report and literature review.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticonvulsants; Brain; Cerebral Ventriculography; D | 2019 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Humans; Lacosa | 2019 |
A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus.
Topics: Algorithms; Anticonvulsants; Bias; Humans; Injections, Intravenous; Models, Statistical; Phenobarbit | 2013 |
Efficacy and safety of intravenous valproate for status epilepticus: a systematic review.
Topics: Administration, Intravenous; Adult; Age Factors; Anticonvulsants; Child; Humans; Status Epilepticus; | 2014 |
The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.
Topics: Amides; Animals; Anticonvulsants; Humans; Status Epilepticus; Stereoisomerism; Valproic Acid | 2015 |
New experimental therapies for status epilepticus in preclinical development.
Topics: Animals; Anticonvulsants; Dictyostelium; Diet, Ketogenic; Drug Evaluation, Preclinical; Humans; Phos | 2015 |
Pharmacologic treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Humans; Ketamine; Levetiracetam; Piracetam; Randomized Controlled | 2016 |
Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Piracetam; Status Epilepticus; Valproic Acid | 2016 |
Review and update of the Hong Kong Epilepsy Guideline on status epilepticus.
Topics: Acetamides; Anticonvulsants; Diet, Ketogenic; Hong Kong; Humans; Lacosamide; Levetiracetam; Magnesiu | 2017 |
[Drugs for status epilepticus treatment].
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Fructose; Humans; Hypnotics and Sedatives; Levetirac | 2009 |
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Topics: Anticonvulsants; Benzodiazepines; Humans; Levetiracetam; Phenobarbital; Phenytoin; Piracetam; Prodru | 2009 |
[Efficacy and safety of intravenous valproates].
Topics: Anticonvulsants; Headache; Humans; Injections, Intravenous; Status Epilepticus; Valproic Acid | 2010 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
IV Valproate in generalized convulsive status epilepticus: a systematic review.
Topics: Administration, Intravenous; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Female; Hu | 2012 |
A systematic review of randomized controlled trials on the theraputic effect of intravenous sodium valproate in status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Injections, Intravenous; Levetiracetam; Phenytoin; Piracetam; Ran | 2012 |
Nonconvulsive status epilepticus in pediatric populations: diagnosis and management.
Topics: Acetazolamide; Anticonvulsants; Benzodiazepines; Child; Clobazam; Electroencephalography; Humans; Lo | 2012 |
Recent developments in treatment of status epilepticus: a review.
Topics: Anticonvulsants; Humans; Injections; Midazolam; Propofol; Status Epilepticus; Valproic Acid | 2002 |
New management strategies in the treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Emergency Medical Services; Humans; Phenobarbital; Phenytoin; Stat | 2003 |
Acute management of seizures in the syndromes of idiopathic generalized epilepsies.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Clonazepam; Comorbidity; Drug Administration Sche | 2003 |
A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders.
Topics: Angelman Syndrome; Anticonvulsants; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, H | 2003 |
Efficacy of rapid IV administration of valproic acid for status epilepticus.
Topics: Anticonvulsants; Comorbidity; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusio | 2005 |
Role of valproate across the ages. Treatment of epilepsy in children.
Topics: Anticonvulsants; Child; Epilepsies, Myoclonic; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epi | 2006 |
The management of refractory status epilepticus: an update.
Topics: Anesthetics; Anticonvulsants; Clinical Protocols; Decision Trees; Drug Administration Schedule; Drug | 2006 |
The use of valproate and new antiepileptic drugs in status epilepticus.
Topics: Anticonvulsants; Drug Approval; Fructose; Humans; Infusions, Intravenous; Injections, Intravenous; L | 2007 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Therapy for status epilepticus.
Topics: Acetazolamide; Anesthesia; Anticonvulsants; Barbiturates; Chlormethiazole; Clonazepam; Diazepam; Eth | 1983 |
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
The epileptic mother and her child.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Fetal | 1982 |
Recent developments in the diagnosis and therapy of epilepsy.
Topics: Anticonvulsants; Biofeedback, Psychology; Carbamazepine; Clonazepam; Clorazepate Dipotassium; Condit | 1982 |
Intravenous valproate in neuropsychiatry.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials | 2000 |
The role of intravenous valproic acid in status epilepticus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anticonvulsants; Child; Humans; Infusions, Intr | 2000 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Midazola | 2001 |
Intravenous valproate in status epilepticus.
Topics: Adult; Anticonvulsants; Child; Humans; Injections, Intravenous; Status Epilepticus; Valproic Acid | 2001 |
The current state of treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Benzodiazepines; Brain; Electroencephalography; Female; GABA Modulators; H | 2002 |
[Status epilepticus and its treatment].
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Epilepsia Partialis Continua; Epilepsies, Par | 2002 |
Valproate: an updated review.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Dyskinesi | 1985 |
Use of ethosuximide and valproate in the treatment of epilepsy.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Drug Interactions; Epilepsies, Myoclonic; Epilepsies, P | 1986 |
Status epilepticus.
Topics: Adult; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Humans; Infant, Newborn; Lidoc | 1986 |
32 trials available for valproic acid and Absence Status
| Article | Year |
|---|---|
Phenobarbital versus valproate for generalized convulsive status epilepticus in adults (2): A multicenter prospective randomized controlled trial in China (China 2-P vs. V).
Topics: Adult; Anticonvulsants; China; Humans; Phenobarbital; Prospective Studies; Status Epilepticus; Valpr | 2021 |
Comparison of the effect of continuous intravenous infusion of sodium valproate and midazolam on management of status epilepticus in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous | 2021 |
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
Long-term follow-up of phenobarbital versus valproate for generalized convulsive status epilepticus in adults: A randomized clinical trial.
Topics: Adult; Anticonvulsants; Diazepam; Follow-Up Studies; Humans; Phenobarbital; Status Epilepticus; Trea | 2023 |
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Double-Blind Method; D | 2019 |
Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial.
Topics: Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Intention to | 2020 |
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Child; C | 2020 |
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Dose-Response Relationship, Drug; Female; Humans; L | 2020 |
Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE).
Topics: Aged; Aged, 80 and over; Anticonvulsants; Double-Blind Method; Female; Germany; Humans; Levetiraceta | 2020 |
Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; | 2021 |
Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Comparative Effectiveness Research; Doub | 2021 |
Comparison of lacosamide versus sodium valproate in status epilepticus: A pilot study.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants | 2017 |
Sodium valproate compared to phenytoin in treatment of status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Drug Resistance; Female; Humans; Infusions, Intraveno | 2018 |
Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalog | 2019 |
Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Child; Child, Preschool; Comparative Effect | 2013 |
The established status epilepticus trial 2013.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Double-Blind M | 2013 |
Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2015 |
A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Infant; Le | 2016 |
Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China.
Topics: Administration, Intravenous; Adult; Anticonvulsants; China; Diazepam; Epilepsy; Female; Humans; Male | 2016 |
Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Brain; Drug-Related Side Effects and Adverse Reactions; | 2008 |
Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; China; Diazepam; Female; Humans; | 2009 |
Management of refractory status epilepticus at a tertiary care centre in a developing country.
Topics: Adolescent; Adult; Anticonvulsants; Developing Countries; Electroencephalography; Female; Humans; In | 2010 |
Improvement in verbal memory after withdrawal of carbamazepine and valproate in patients with well-controlled epilepsy: a randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Double-Blind Method; Female; Humans; Male; | 2011 |
Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Cerebrovascular Disorders; Diazepam; Drug Resistance; Electroencephalo | 2011 |
Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infusions, Intravenous; Male; | 2012 |
Intravenous sodium valproate in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Female; Humans; Injections, Intravenous; Male; Middle Aged; Stat | 2003 |
Rapid infusion with valproate sodium is well tolerated in patients with epilepsy.
Topics: Acute Disease; Anticonvulsants; Blood Pressure; Cohort Studies; Dose-Response Relationship, Drug; Dr | 2004 |
Cognitive deterioration and electrical status epilepticus during slow sleep.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Cognition Disorders; Electroe | 2005 |
Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus--experience in 102 adult patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Female; Humans; Inject | 2005 |
Sodium valproate vs phenytoin in status epilepticus: a pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Male; Midd | 2006 |
Randomized study of intravenous valproate and phenytoin in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Case-Control Studies; Child; Double-Blind Method; Female; Follow | 2007 |
Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Female; Humans; Hypotension; Infant; Infusions, | 2007 |
181 other studies available for valproic acid and Absence Status
| Article | Year |
|---|---|
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
Topics: Animals; Anticonvulsants; Carbamates; Male; Mice; Neurotoxicity Syndromes; Rats; Rats, Sprague-Dawle | 2012 |
Anticonvulsive Effects of Chondroitin Sulfate on Pilocarpine and Pentylenetetrazole Induced Epileptogenesis in Mice.
Topics: Animals; Anticonvulsants; Chondroitin Sulfates; Male; Mice; Molecular Docking Simulation; Neuroprote | 2021 |
Novel UBE3A pathogenic variant in a large Georgian family produces non-convulsive status epilepticus responsive to ketogenic diet.
Topics: Benzodiazepines; Child, Preschool; Diet, Ketogenic; Electroencephalography; Georgia (Republic); Huma | 2022 |
Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Topics: Administration, Intravenous; Anticonvulsants; Humans; Retrospective Studies; Status Epilepticus; Val | 2022 |
An aqueous extract of Syzygium cumini protects against kainate-induced status epilepticus and amnesia: evidence for antioxidant and anti-inflammatory intervention.
Topics: Amnesia; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Kainic Acid; Mice; Pirace | 2022 |
Neural excitatory rebound induced by valproic acid may predict its inadequate control of seizures.
Topics: Animals; Anticonvulsants; China; Mice; Seizures; Status Epilepticus; Valproic Acid | 2022 |
A novel de novo TET3 loss-of-function variant in a Turkish boy presenting with neurodevelopmental delay and electrical status epilepticus during slow-wave sleep.
Topics: Child; Clobazam; Dioxygenases; Electroencephalography; Humans; Infant; Male; Sleep; Sleep, Slow-Wave | 2023 |
Imatinib Attenuates Pentylenetetrazole Kindled and Pilocarpine Induced Recurrent Spontaneous Seizures in Mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Imatinib Mesylate; Mice; Pentylenetetraz | 2023 |
Dynamic effects of miR-20a-5p on hippocampal ripple energy after status epilepticus in rats.
Topics: Animals; Chloral Hydrate; Hippocampus; MicroRNAs; Pilocarpine; Rats; Seizures; Status Epilepticus; V | 2023 |
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment.
Topics: Adult; Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2023 |
Idiopathic generalized epilepsy with phantom absences, absence status, and generalized tonic-clonic seizures: A case report.
Topics: Adult; Electroencephalography; Epilepsy, Absence; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Fem | 2023 |
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Child; Female; Hospitals, Universi | 2023 |
De novo Absence Status Epilepticus in a pediatric cohort: Electroclinical pattern in a multicenter Italian patients cohort.
Topics: Adolescent; Anticonvulsants; Child; Electroencephalography; Epilepsy; Ethosuximide; Female; Humans; | 2019 |
Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus.
Topics: Aged; Anticonvulsants; Cohort Studies; Drug Prescriptions; Drug Resistant Epilepsy; Female; Humans; | 2020 |
Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome.
Topics: Anticonvulsants; Child; Clobazam; Drug Therapy, Combination; Epilepsies, Myoclonic; Fenfluramine; Hu | 2020 |
Characterization and treatment of spontaneous recurrent seizures following nerve agent-induced status epilepticus in mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Levetiracetam; Mice; Nerve Agents; Phenobarbital; | 2020 |
Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine.
Topics: Anticonvulsants; Clobazam; Enterovirus A, Human; Enterovirus Infections; Epilepsy; Fatal Outcome; Fe | 2020 |
Pediatric Convulsive Status Epilepticus: Act Fast, No matter With What!
Topics: Child; Double-Blind Method; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Valproic Acid | 2020 |
Second-line anticonvulsants for paediatric convulsive status epilepticus.
Topics: Anticonvulsants; Child; Double-Blind Method; Humans; Levetiracetam; Phenytoin; Status Epilepticus; V | 2020 |
Choosing Anticonvulsant Medications to Manage Status Epilepticus.
Topics: Adult; Anticonvulsants; Disease Management; Drug Therapy, Combination; Epilepsy, Generalized; Female | 2020 |
Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
Topics: Adult; Aged; Anticonvulsants; Clinical Decision-Making; Cohort Studies; Female; Humans; Hyperammonem | 2020 |
Accuracy of Calculated Free Valproate Levels in Adult Patients With Status Epilepticus.
Topics: Aged; Anticonvulsants; Blood Chemical Analysis; Female; Humans; Male; Middle Aged; Serum Albumin; St | 2021 |
Neuroprotection by delayed triple therapy following sarin nerve agent insult in the rat.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carrier Proteins; Dinoprostone; Disease Models, A | 2021 |
Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Topics: Adult; Ammonia; Anticonvulsants; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2021 |
Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect.
Topics: Adult; Child; Humans; Hyperammonemia; Ornithine Carbamoyltransferase Deficiency Disease; Status Epil | 2021 |
The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined?
Topics: Acetamides; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; He | 2017 |
Simultaneous triple therapy for the treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Brain Waves; Combined Modality Therapy; Disease Models, Animal; Dose-Respo | 2017 |
Treatment outcomes after the introduction of a new seizure management protocol.
Topics: Adult; Anticonvulsants; Clinical Protocols; Drug-Related Side Effects and Adverse Reactions; Emergen | 2018 |
Effects of gap junctions blockers on fast ripples and connexin in rat hippocampi after status epilepticus.
Topics: Animals; Anticonvulsants; Carbenoxolone; Connexins; Electrocorticography; Gap Junctions; Gene Expres | 2018 |
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Topics: Adolescent; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Drug Therapy, Combination; Epilep | 2019 |
De novo absence status epilepticus in three paediatric patients: a new idiopathic epilepsy syndrome?
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; | 2018 |
Valproate and the Pregnancy Prevention Programme: exceptional circumstances.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Drug and Narcotic Control; Europe; Female; Humans; Pre | 2019 |
Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carnitine; Female; Humans; Hyperammonemia; Injectio | 2019 |
Suppressive effects of levetiracetam on neuroinflammation and phagocytic microglia: A comparative study of levetiracetam, valproate and carbamazepine.
Topics: Animals; Anticonvulsants; Carbamazepine; Cells, Cultured; Cytokines; Inflammation; Levetiracetam; Ma | 2019 |
Acquired epileptiform opercular syndrome evaluated with real-time transcranial Doppler ultrasound-video-electroencephalogram before and after treatment: a case report.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Humans; Male; Methylprednisolone; Seizure | 2019 |
Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Neurotoxicity Syndromes; Status Epilepticus; Valproic Acid | 2020 |
Effects of Three Anti-Seizure Drugs on Cholinergic and Metabolic Activity in Experimental Status Epilepticus.
Topics: Acetylcholine; Animals; Anticonvulsants; Behavior, Animal; Cholinergic Agents; Chromatography, High | 2019 |
The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus.
Topics: Animals; Behavior, Animal; Cell Death; Diazepam; Disease Models, Animal; Drug Therapy, Combination; | 2013 |
Intravenous valproate in twelve patients with post-anoxic status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Cardiopulmonary Resuscitation; Cohort Studies; Dose-Response Relatio | 2013 |
Clinical experience with intravenous valproate as first-line treatment of status epilepticus and seizure clusters in selected populations.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Electroencephalography; Female; Humans; Injections, Intrav | 2014 |
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.
Topics: Acetamides; Amides; Animals; Anticonvulsants; Disease Models, Animal; Rats; Soman; Status Epilepticu | 2013 |
Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus.
Topics: Acute Disease; Amides; Animals; Anticonvulsants; Disease Models, Animal; Guinea Pigs; Humans; Rats; | 2013 |
Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid.
Topics: Animals; Anticonvulsants; Cells, Cultured; GABA Antagonists; Hippocampus; Kainic Acid; Male; Neurons | 2014 |
Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.
Topics: Amides; Animals; Anticonvulsants; Central Nervous System Stimulants; Male; Mice; Neural Tube Defects | 2014 |
[Case of non-convulsive status epilepticus after influenza virus B infection].
Topics: Adult; Anticonvulsants; Electroencephalography; Female; Humans; Influenza B virus; Influenza, Human; | 2014 |
Lacosamide in children with refractory status epilepticus. A multicenter Italian experience.
Topics: Acetamides; Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Hu | 2014 |
Degeneration and regeneration of GABAergic interneurons in the dentate gyrus of adult mice in experimental models of epilepsy.
Topics: Animals; Chronic Disease; Dentate Gyrus; Epilepsy; GABAergic Neurons; Glutamate Decarboxylase; Green | 2015 |
sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.
Topics: Amides; Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Insecticides; Male | 2014 |
Mixed myoclonic-absence status epilepticus in juvenile myoclonic epilepsy.
Topics: Anticonvulsants; Bipolar Disorder; Catatonia; Clonazepam; Electroencephalography; Epilepsies, Myoclo | 2015 |
[Dramatic seizure reduction with levetiracetam in adult Dravet syndrome: a case report].
Topics: Adult; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Levetiracetam; Male; Piracetam; Sta | 2015 |
Evaluation of the efficacy of sodium valproate in convulsive status epilepticus following to ıschemic stroke.
Topics: Administration, Intravenous; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; | 2015 |
Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats.
Topics: Adenosine; Animals; Anticonvulsants; Diet, Ketogenic; Disease Models, Animal; Disease Progression; D | 2015 |
[Cases of non-standard approach to treatment of super-refractory status epilepticus].
Topics: Adult; Anesthetics, Intravenous; Anticonvulsants; Clinical Protocols; Drug Therapy, Combination; Ele | 2015 |
Case report: absence-status as late reexacerbation of genetic epilepsy of adolescence.
Topics: Adolescent; Age of Onset; Anticonvulsants; Electroencephalography; Epilepsy, Absence; Humans; Leveti | 2016 |
Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Drug Resistance; Epilepsy; GABA Antagoni | 2016 |
Tonic Seizure Status Epilepticus Triggered by Valproate in a Child with Doose Syndrome.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsies, Myoclonic; Humans; Male; Seizures; Statu | 2016 |
A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Protocol | 2016 |
Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus.
Topics: Administration, Intravenous; Amides; Animals; Anticonvulsants; Benzodiazepines; Brain; Central Nervo | 2016 |
Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP.
Topics: Adolescent; Adult; Anticonvulsants; Bayes Theorem; Cohort Studies; Epilepsy; Female; Humans; Interna | 2016 |
Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.
Topics: Animals; Anticonvulsants; Brain; Cholinergic Agents; Disease Models, Animal; Drug Synergism; Drug Th | 2016 |
Status epilepticus in central nervous system infections: an experience from a developing country.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Central Nervous System Infections; Developing Countries; D | 2008 |
The role of the newer antiepileptic drugs in the treatment of generalized convulsive status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Piracetam; Status Epilepticus; Valproic Acid | 2008 |
Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, Partial; Fema | 2009 |
Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Drug Administration Schedule; Drug | 2010 |
Rational treatment options with AEDs and ketogenic diet in Landau-Kleffner syndrome: still waiting after all these years.
Topics: Anticonvulsants; Behavior Therapy; Benzodiazepines; Child; Combined Modality Therapy; Diet, Ketogeni | 2009 |
Predictors and prognosis of status epilepticus treated with intravenous sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Data Interpretation, Statistical; Female; Humans; Injections, In | 2009 |
Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children.
Topics: Adolescent; Ammonia; Anticonvulsants; Child; Child, Preschool; Cross-Sectional Studies; Epilepsy; Fe | 2011 |
Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome.
Topics: Adolescent; Anticonvulsants; Child; Cognition Disorders; Drug Therapy, Combination; Electroencephalo | 2010 |
Probable valproate sodium-associated hypotension.
Topics: Aged; Anticonvulsants; Fluid Therapy; Humans; Hypotension; Infusions, Intravenous; Male; Status Epil | 2010 |
[Non-convulsive status epilepticus in 12-year-old].
Topics: Anticonvulsants; Child; Clonazepam; Diagnosis, Differential; Electroencephalography; Female; Humans; | 2010 |
The role of intravenous valproate in convulsive status epilepticus in the future.
Topics: Anticonvulsants; Humans; Injections, Intravenous; Liver; Pancreatitis; Phenytoin; Practice Guideline | 2010 |
[Malignant migrating partial seizures of infancy: the experience of treatment of status epilepticus in infancy using intravenous valproate--convulex (a clinical case)].
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Humans; Infant; Injections, Intravenou | 2010 |
Unilateral continuous subclinical paroxysmal activity: an unusual finding in a patient with recurrent absence status.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Diagnosis, Differential; Dose-Response Relationship, D | 2010 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Clinical Protocols; Fructose; GABA Modulators; Humans; Keta | 2011 |
Valproate decreases frequency facilitation at mossy fiber--CA3 synapses after status epilepticus.
Topics: Animals; Anticonvulsants; CA3 Region, Hippocampal; Electric Stimulation; Electrodes, Implanted; Elec | 2011 |
[Modern conceptions on the status epilepticus and possibilities of treatment with injection form of valproate (convulex)].
Topics: Anticonvulsants; Emergency Services, Psychiatric; Humans; Status Epilepticus; Valproic Acid | 2010 |
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam.
Topics: Aged; Analysis of Variance; Anticonvulsants; Chi-Square Distribution; Female; Humans; Levetiracetam; | 2011 |
[Acute valproic acid intoxication: interest of a treatment by extracoporeal elimination combined with L-carnitine].
Topics: Acidosis, Lactic; Acute Lung Injury; Anticonvulsants; Carnitine; Cranial Nerve Diseases; Electroence | 2011 |
A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.
Topics: Amides; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2012 |
[Delirium caused by nonconvulsive status epilepticus].
Topics: Affect; Aged; Anticonvulsants; Antipsychotic Agents; Brain Edema; Confusion; Delirium; Dibenzothiaze | 2012 |
Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Disease Management; Emer | 2012 |
Valproate-induced panhypogammaglobulinemia.
Topics: Agammaglobulinemia; Anticonvulsants; Female; Humans; Infant; Pancytopenia; Status Epilepticus; Valpr | 2013 |
Comparison of triphasic waves and epileptic discharges in one patient with genetic epilepsy.
Topics: Anticonvulsants; Brain; Brain Mapping; Brain Waves; Diagnosis, Differential; Electroencephalography; | 2012 |
Treatment of status epilepticus: an international survey of experts.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Child; Consensus; Expert Testimony; Humans; Hyp | 2013 |
[Epilepsies with electric status epilepticus in sleep: peculiarities of clinical course and rational approaches to treatment].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Resistance; Electricity; E | 2011 |
A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus.
Topics: Amides; Animals; Anticonvulsants; Cerebral Cortex; Diazepam; Dose-Response Relationship, Drug; Elect | 2013 |
Seizure control by ketogenic diet-associated medium chain fatty acids.
Topics: Animals; Anticonvulsants; Caprylates; Cell Line; Chemical and Drug Induced Liver Injury; Convulsants | 2013 |
Non convulsive status epilepticus after replacement of valproate with lamotrigine.
Topics: Adult; Aged; Anticoagulants; Benzodiazepines; Electroencephalography; Epilepsy, Generalized; Female; | 2002 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
A case of nonconvulsive status epilepticus associated with focal cortical dysplasia.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Diseases; Cerebral Cortex; Child; Child | 2003 |
Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dru | 2003 |
Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.
Topics: Administration, Oral; Adult; Ammonia; Anticonvulsants; Confusion; Drug Interactions; Drug Therapy, C | 2003 |
The vegetarian who ate a sausage with curry sauce.
Topics: Anticonvulsants; Behavior; Diet, Vegetarian; Electrocardiography; Electroencephalography; Female; Hu | 2003 |
Out-of-hospital management of benzodiazepine-resistant status epilepticus in a child with Wolf-Hirschhorn syndrome.
Topics: Abnormalities, Multiple; Anticonvulsants; Apnea; Child; Chromosome Deletion; Chromosomes, Human, Pai | 2003 |
Nonconvulsive status epilepticus.
Topics: Anticonvulsants; Electroencephalography; Humans; Liver Failure; MELAS Syndrome; Prognosis; Retrospec | 2003 |
Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region.
Topics: 4-Aminopyridine; Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Intravenous valproate in post-anoxic myoclonic status epilepticus: a report of ten patients.
Topics: Adolescent; Adult; Anticonvulsants; Electroencephalography; Epilepsies, Myoclonic; Female; Humans; H | 2004 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Inhibition of persistent sodium current fraction and voltage-gated L-type calcium current by propofol in cortical neurons: implications for its antiepileptic activity.
Topics: Action Potentials; Animals; Anticonvulsants; Calcium Channels, L-Type; Frontal Lobe; In Vitro Techni | 2005 |
Efficacy of rapid IV administration of valproic acid for status epilepticus.
Topics: Anticonvulsants; Brain; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencep | 2005 |
Nonconvulsive status epilepticus: clinical features and diagnostic challenges.
Topics: Adolescent; Aged; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Female; Humans; | 2005 |
Prolonged postictal stupor: nonconvulsive status epilepticus, medication effect, or postictal state?
Topics: Adult; Anticonvulsants; Benzodiazepines; Coma; Diagnosis, Differential; Electroencephalography; Epil | 2005 |
Transient occipitotemporal subcortical diffusion-weighted magnetic resonance imaging abnormalities associated with status epilepticus. Case report.
Topics: Adult; Carbamazepine; Diazepam; Diffusion Magnetic Resonance Imaging; Drug Administration Schedule; | 2006 |
Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Body Weight; Cell Death; Disease Models, Animal; Dose-Re | 2006 |
Nonconvulsive status epilepticus and neurodevelopmental delay.
Topics: Anticonvulsants; Developmental Disabilities; Electroencephalography; Humans; Infant; Male; Status Ep | 2006 |
Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus.
Topics: Acute Disease; Electroencephalography; Female; Humans; Injections, Intravenous; Middle Aged; Neuroto | 2006 |
Meropenem -valproic acid interaction in patients with cefepime-associated status epilepticus.
Topics: Anti-Bacterial Agents; Anticonvulsants; Cefixime; Ceftazidime; Drug Interactions; Female; Humans; Ma | 2007 |
The challenges of psychopharmacological management of children with severe developmental disabilities.
Topics: Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Caregivers; Child; Developmental Disabilit | 2006 |
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy.
Topics: Adult; Age Factors; Anesthesia, General; Anticonvulsants; Benzodiazepines; Humans; International Age | 2006 |
Sodium valproate vs phenytoin in status epilepticus: a pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Male; Midd | 2007 |
Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, General; Anticonvulsants; Dose-Response Relationship, D | 2007 |
Nonconvulsive status epilepticus in a neurological intensive care unit: profile in a developing country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Central Nervous System Infections; Chil | 2007 |
Anti-glutamatergic effect of riluzole: comparison with valproic acid.
Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Epilepsy, Absence; Excitatory Posts | 2007 |
Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Topics: Adult; Ammonia; Anticonvulsants; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; Hype | 2007 |
Absence status epilepsy: delineation of a distinct idiopathic generalized epilepsy syndrome.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Anticonvulsants; Benzodiazepines; Child; Comorbi | 2008 |
Nitromethane encephalopathy MRI.
Topics: Adolescent; Anticonvulsants; Brain; Cerebellar Diseases; Cerebellum; Epilepsy, Tonic-Clonic; Humans; | 2008 |
Simultaneous toxicities in a child on multiple anticonvulsants.
Topics: Anticonvulsants; Bone Marrow; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child, P | 2008 |
Re: New lessons: classic treatments in convulsive status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Humans; Lorazepam; Phenytoin; Status Epilepticus; Valpro | 2008 |
A monkey model for status epilepticus: carbamazepine and valproate compared to three standard anticonvulsants.
Topics: Aluminum Hydroxide; Animals; Anticonvulsants; Carbamazepine; Diazepam; Macaca mulatta; Male; Phenoba | 1983 |
Clinical pharmacokinetics of drugs used in the treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Female; Humans; Kinetics; Models, Biologica | 1983 |
Valproic acid in the treatment of status epilepticus.
Topics: Adult; Female; Humans; Male; Status Epilepticus; Valproic Acid | 1983 |
Tonic status epilepticus presenting as confusional state.
Topics: Adolescent; Cognition Disorders; Confusion; Diazepam; Electroencephalography; Humans; Male; Methylph | 1983 |
[Status epilepticus treated with barbiturate anesthesia and sodium valproate].
Topics: Adult; Anesthesia, Intravenous; Drug Therapy, Combination; Humans; Male; Status Epilepticus; Thiamyl | 1983 |
Drugs for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Drug Interactions; Epilepsy; Humans; Phenobarbital; Phenytoin; Statu | 1983 |
Reye-like syndrome associated with valproic acid.
Topics: Adolescent; Ammonia; Biopsy; Female; Humans; Liver; Liver Function Tests; Reye Syndrome; Status Epil | 1983 |
[Pharmacotherapy of epilepsy--current problems and controversies].
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy, | 1983 |
Pharmacologic therapy of seizures in the elderly.
Topics: Aged; Anticonvulsants; Carbamazepine; Humans; Phenobarbital; Phenytoin; Primidone; Seizures; Status | 1984 |
Absence status in adults.
Topics: Adult; Clonazepam; Electroencephalography; Female; Humans; Male; Middle Aged; Status Epilepticus; Va | 1983 |
Rectal administration of sodium valproate for neonatal and infantile status epilepticus.
Topics: Humans; Infant; Infant, Newborn; Status Epilepticus; Suppositories; Valproic Acid | 1984 |
Rectal administration of sodium valproate in status epilepticus.
Topics: Humans; Rectum; Status Epilepticus; Valproic Acid | 1980 |
[Termination of status epilepticus by means of sodium-valproate (author's transl)].
Topics: Humans; Infant; Male; Status Epilepticus; Valproic Acid | 1980 |
Rectal valproate syrup and status epilepticus.
Topics: Aged; Drug Therapy, Combination; Humans; Male; Rectum; Status Epilepticus; Valproic Acid | 1980 |
[Termination of status epilepticus with sodium valproate].
Topics: Clonazepam; Diazepam; Humans; Infant; Phenytoin; Status Epilepticus; Valproic Acid | 1980 |
Pharmacologic advances in seizure control.
Topics: Anticonvulsants; Carbamazepine; Child; Clonazepam; Humans; Kinetics; Phenytoin; Seizures; Status Epi | 1981 |
Temporary abolition of seizure activity by flumazenil.
Topics: Flumazenil; Humans; Status Epilepticus; Valproic Acid | 1994 |
Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female | 1993 |
[Hemorrhagic shock and fulminant hepatic failure associated with valproate].
Topics: Anticonvulsants; Child; Hepatic Encephalopathy; Humans; Liver; Male; Shock, Hemorrhagic; Status Epil | 1995 |
Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus.
Topics: Animals; Anticonvulsants; Baclofen; Clonazepam; Diazepam; Dizocilpine Maleate; Ethanol; GABA Agents; | 1996 |
Valproate in status epilepticus.
Topics: Animals; Anticonvulsants; Biological Availability; Clinical Trials as Topic; Drug Evaluation, Precli | 1995 |
Valproate toxicity.
Topics: Adolescent; Humans; Liver Failure; Male; Status Epilepticus; Valproic Acid | 1996 |
Status epilepticus associated with the combination of valproic acid and clomipramine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Female; | 1997 |
Nonconvulsive status epilepticus with generalized 'fast activity'.
Topics: Alpha Rhythm; Anticonvulsants; Cerebral Cortex; Diagnosis, Differential; Drug Therapy, Combination; | 1997 |
[Valproate i.v. Survey of its clinical application].
Topics: Anticonvulsants; Humans; Injections, Intravenous; Status Epilepticus; Valproic Acid | 1997 |
Psychogenic status epilepticus.
Topics: Adult; Anticonvulsants; Humans; Male; Placebos; Psychophysiologic Disorders; Status Epilepticus; Val | 1997 |
Nonconvulsive status epilepticus.
Topics: Anticonvulsants; Dizziness; Electroencephalography; Emergency Service, Hospital; Epilepsy, Tonic-Clo | 1997 |
Negative myoclonic status due to antiepileptic drug tapering: report of three cases.
Topics: Adolescent; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebral | 1997 |
[Partial complex status epilepticus: diagnostic difficulties].
Topics: Anticonvulsants; Child; Crime; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalog | 1998 |
Comparison of valproate and phenobarbital treatment after status epilepticus in rats.
Topics: Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Agonists; | 1998 |
Valproate-induced epileptic tonic status.
Topics: Adolescent; Ammonia; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epilepsy, T | 1998 |
Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status.
Topics: Adult; Electroencephalography; Epilepsy, Absence; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Evo | 1998 |
Intravenous valproate treatment of generalized nonconvulsive status epilepticus.
Topics: Adult; Anticonvulsants; Electroencephalography; Female; Humans; Infusions, Intravenous; Monitoring, | 1999 |
An unusual case of Lafora body disease.
Topics: Adolescent; Cerebral Cortex; Electroencephalography; Fatal Outcome; Humans; Lafora Disease; Male; St | 1999 |
Status epilepticus during pregnancy. A case report.
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Obstetric Labor Complications; Pregnancy; Pr | 1999 |
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid.
Topics: Adult; Child; Electroencephalography; Humans; Infant; Injections, Intravenous; Male; Status Epilepti | 1999 |
Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Drug Interactions; Enzyme In | 1999 |
Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.
Topics: Anticonvulsants; Child; Female; Fluid Therapy; Humans; Hypotension; Infusions, Intravenous; Status E | 1999 |
Treatment of refractory complex-partial status epilepticus with propofol: case report.
Topics: Aged; Anticonvulsants; Drug Interactions; Drug Resistance, Multiple; Electroencephalography; Epileps | 2000 |
Intravenous valproic acid for myoclonic status epilepticus.
Topics: Adolescent; Adult; Epilepsies, Myoclonic; Female; Humans; Status Epilepticus; Valproic Acid | 2000 |
Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Female; Humans; Infant; Infan | 2000 |
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized; | 1999 |
Intravenous valproate is well tolerated in unstable patients with status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Heart Rate; Humans; Hypotension; Infusions, Intraven | 2000 |
Nonconvulsive status epilepticus causing acute confusion.
Topics: Aged; Anti-Anxiety Agents; Diazepam; Female; Humans; Neuroleptic Malignant Syndrome; Status Epilepti | 2001 |
Myoclonic status epilepticus: video presentation.
Topics: Adult; Combined Modality Therapy; Female; Humans; Myoclonic Epilepsy, Juvenile; Psychotherapy; Statu | 2002 |
Valproic acid therapy inducing absence status evolving into generalized seizures.
Topics: Anticonvulsants; Child; Child, Preschool; Female; Humans; Male; Seizures; Status Epilepticus; Valpro | 2002 |
Rectal valproate in intractable status epilepticus.
Topics: Adolescent; Adult; Female; Humans; Male; Rectum; Status Epilepticus; Suppositories; Valerates; Valpr | 1977 |
Rectal administration of sodium valproate in status epilepticus.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Status Epilepticus; Suppositories; Valproic Ac | 1978 |
Drugs for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Diazepam; Epilepsy; Ethosuximide; Humans; Phenobarbital; | 1979 |
Valproic acid treatment of experimental status epilepticus.
Topics: Animals; Dose-Response Relationship, Drug; Electroencephalography; Male; Rats; Rats, Sprague-Dawley; | 1992 |
Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.
Topics: Brain; Chemical and Drug Induced Liver Injury; Diagnostic Errors; Diffuse Cerebral Sclerosis of Schi | 1992 |
[Effect of anticonvulsants upon experimental limbic seizure status and regional cerebral blood flow in the hippocampus].
Topics: Animals; Anticonvulsants; Cats; Diazepam; Electroencephalography; Hippocampus; Isoxazoles; Phenobarb | 1992 |
Absence status.
Topics: Humans; Status Epilepticus; Valproic Acid | 1990 |
The effect of hemodialysis and hemoperfusion on serum valproic acid concentration.
Topics: Female; Hemoperfusion; Humans; Kinetics; Middle Aged; Renal Dialysis; Status Epilepticus; Valproic A | 1990 |
[Case of epilepsy in an infant with fatal outcome during the 1st year of unknown etiology].
Topics: Developmental Disabilities; Drug Resistance; Electroencephalography; Epilepsy; Humans; Infant; Infan | 1985 |
Drugs for epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Humans; Phenytoin; Status | 1986 |
Valproic acid in neonatal status convulsivus.
Topics: Humans; Infant, Newborn; Male; Status Epilepticus; Valproic Acid | 1986 |
Status epilepticus within the Lennox-Gastaut syndrome: clinical characteristics and management.
Topics: Child; Clonazepam; Electroencephalography; Epilepsy; Humans; Male; Status Epilepticus; Syndrome; Val | 1987 |
Rectal anticonvulsants in pediatric practice.
Topics: Administration, Rectal; Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child, Preschoo | 1988 |
[Treatment of status epilepticus by sodium valproate].
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Child; Child, Preschool; Fema | 1988 |
[Treatment of refractory status convulsivus with chlormethiazole].
Topics: Child, Preschool; Chlormethiazole; Female; Humans; Infusions, Intravenous; Respiration Disorders; St | 1988 |
Treatment of status epilepticus in children with rectal sodium valproate.
Topics: Adolescent; Aspartate Aminotransferases; Child; Child, Preschool; Electroencephalography; Enema; Fem | 1985 |